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Abstract
For fifty years, tremendous efforts have been directed towards the devel-
opment of glucose sensors for tight glycemic control of diabetic patients.
Today, millions of diabetics test their blood glucose level daily, making
glucose the most commonly tested analyte. Recently, subcutaneous im-
plantable needle-type sensors became commercially available for continu-
ous glucose monitoring. However, these devices require frequent calibra-
tions and are lacking accuracy and reliability. They are based on electro-
chemical detection, which is strongly affected by the biological environ-
ment in which the sensor is placed. In addition, an accurate and reliable
continuous glucose sensor would also be of great interest for tight glycemic
control in intensive care units of hospitals. However, despite the many im-
pressive breakthroughs, the development of clinically accurate continuous
glucose sensors remains a challenge.
In this context, alternative approaches to overcome the limitation of
electrochemical methods have been actively investigated. Among these,
affinity sensing should offer several intrinsic advantages for in vivo mon-
itoring. In this thesis, we investigate a novel viscosity-dependent affinity
sensor for continuous monitoring of glucose in biological fluids such as
blood and plasma. The sensing principle relies upon the viscosity varia-
tion of a sensitive fluid with glucose concentration. The sensitive fluid is
based on the competitive binding of glucose and dextran with a glucose-
specific binding protein, Concanavalin A. Basically, the sensor is filled with
the sensitive fluid, and includes both an actuating and a sensing piezo-
electric diaphragm as well as a flow-resistive microchannel. In addition,
a nanoporous alumina membrane completely retains the sensitive fluid
within the sensor whilst allowing glucose permeation through the mem-
brane.
The sensor was extensively tested in isotonic saline solution for physio-
logical blood glucose concentrations between 2 and 20 mM, demonstrating
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an excellent accuracy, reversibility and stability for up to 3 days. In addi-
tion, the response time was close to the 10 minutes required for medical ap-
plications. However, despite the excellent short term stability, a progressive
loss of sensitivity was observed for long term measurements. Concanavalin
A retention by the alumina nanoporous membrane was assessed by ultra-
violet absorbance spectrometry. Small leakage through the membrane was
detected, which at least partly explains the sensitivity reduction over sev-
eral days. Finally, the adequacy of the sensor for measurement in human
blood serum and plasma was checked. Physiological glucose levels were
successfully monitored, meaning that the chemical stability of the sensitive
fluid and biofouling of the nanoporous alumina membrane were not an is-
sue for short term applications. Moreover, interferences from biomolecules
were limited and the sensitivity was still high enough for glucose moni-
toring. These results suggest that the combination of the ConA-based sen-
sitive fluid and the microviscometer is a promising sensing principle for
continuous glucose monitoring in blood.
Keywords: Diabetes, Glucose monitoring, Glucose sensor, Affinity sen-
sor, Micromechanical sensor, Chemico-mechanical sensor, Viscosity, Con-
canavalin A, Dextran, Nanoporous membrane, Alumina membrane.
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Résumé
Depuis cinquante ans, d’importants efforts ont été consentis pour déve-
lopper des capteurs de glucose permettant un contrôle optimal de la gly-
cémie des patients diabétiques. Actuellement, des millions de diabétiques
mesurent quotidiennement leur glycémie, ce qui fait du glucose la sub-
stance la plus fréquemment testée. Récemment, des systèmes de mesure
du glucose en continu utilisant l’insertion d’une aiguille sous-cutanée ont
été commercialisés. Cependant, ces dispositifs nécessitent une calibration
fréquente et manquent de précision et de fiabilité. Ils sont basés sur une
détection électrochimique qui est fortement affectée par l’environnement
biologique dans lequel le capteur est placé. En outre, un capteur de glucose
permettant une mesure continue qui soit précise et fiable aurait aussi un
grand intérêt pour le contrôle de la glycémie dans les unités de soins in-
tensifs. Cependant, malgré les avances technologiques importantes, le dé-
veloppement d’un système permettant une mesure continue du glucose
suffisamment précise reste un défi majeur.
Dans ce contexte, des approches alternatives qui permettraient de sur-
monter les limitations des méthodes électrochimiques ont été investiguées.
Parmi ces dernières, les méthodes utilisant l’affinité spécifique de certains
composés pour le glucose devraient offrir certains avantages pour les me-
sures in vivo. Dans cette thèse, nous investiguons un nouveau principe de
détection pour la mesure continue du glucose dans les liquides biologiques
tels que le sang et le plasma. Le principe de mesure repose sur la variation
de la viscosité d’une solution sensible avec la concentration de glucose. La
solution sensible est basée sur la compétition entre le glucose et le dextran
pour lier la Concanavalin A, une protéine ayant une affinité spécifique pour
le glucose. Plus précisément, le capteur est rempli avec la solution sensible,
et comprend deux diaphragmes piézoélectriques ainsi qu’un micro-canal
permettant de mesurer la viscosité. De plus, une membrane d’alumine na-
noporeuse confine la solution sensible dans le capteur tout en permettant
iii
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la perméation du glucose à travers la membrane.
Le capteur a été testé dans une solution saline isotonique pour des
concentrations physiologiques de glucose entre 2 et 20 mM, démontrant
une excellente précision, réversibilité et stabilité jusqu’à 3 jours. De plus, le
temps de réponse est proche des 10 minutes requises pour des applications
médicales. Cependant, malgré l’excellente stabilité à court terme, une perte
progressive de sensibilité a été observée pour des mesures à long terme.
La rétention de la Concanavalin A par la membrane d’alumine nanopo-
reuse a été évaluée par spectrométrie d’absorption ultraviolette. De petites
fuites ont été détectées, expliquant au moins partiellement la réduction de
sensibilité observée sur plusieurs jours. Enfin, la capacité du capteur à fonc-
tionner dans le sang et le plasma humain a été vérifiée. Différentes concen-
trations physiologiques de glucose ont été mesurées avec succès dans le
plasma humain, ce qui signifie que la stabilité chimique de la solution sen-
sible et l’encrassement biologique de la membrane d’alumine nanoporeuse
n’est pas un problème pour les mesures à court terme. Par ailleurs, les inter-
férences dues aux biomolécules du plasma étaient limitées et la sensibilité
était encore suffisamment élevée pour permettre une mesure précise. Ces
résultats suggèrent que la combinaison de la solution sensible basée sur la
Concanavalin A et du micro-viscosimètre est un principe prometteur pour
la mesure continue du glucose dans le sang.
Mots clé : Diabète, Mesure du glucose, Capteur de glucose, Capteur
d’affinité, Capteur micromécanique, Capteur chimico-mécanique, Viscosité,
Concanavalin A, Dextran, Membrane nanoporeuse, Membrane d’alumine.
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Chapter 1
Introduction
1.1 Glucose-sensing function of pancreas
Glucose concentration in blood is mainly regulated by insulin, which is a
vital hormone secreted by the beta cells of the pancreas (Fig. 1.1). Insulin
makes possible to assimilate nutrients, by triggering the glucose storage
as glycogen in cells of the liver, muscles and fat tissues. The peak secre-
tion of insulin coincides therefore with meals, when a high amount of glu-
cose is absorbed by the body. By allowing the passage of glucose into the
cells, insulin allows energy storage while preventing hyperglycemia after
a meal. Insulin secretion in response to glucose is extremely rapid, occur-
ring within one minute after the glucose concentration increase. When the
glucose concentration is back to a normal level, the insulin secretion stops,
thus avoiding a swing in the opposite direction that would lead to hypo-
glycemia. This mechanism, known as glucose-controlled insulin secretion,
is normally regulating the glycemia. However, if the glucose concentration
drops to dangerous levels, e.g. after an extended period without eating, the
alpha cells of the pancreas release glucagon, an other hormone. Its effect is
opposite that of insulin. This is a safety mechanism which acts to restore
the glucose concentration in the physiological range. The glucagon trig-
gers the conversion of the glycogen of the liver cells into glucose, which is
subsequently released into the blood. The antagonist effects of insulin and
glucagon keep the blood glucose concentration within very narrow limits
(80–120 mg/dl or 4.4–6.6 mM)1 in healthy persons in spite of the fact that
1Both units are commonly used for the glucose concentration (1 mM = 18 mg/dl).
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Figure 1.1: Regulation of the body glycemia: insulin and glucagon have
opposite effects on liver and other tissues for controlling the blood glucose
concentration. (Reprinted from http://health.howstuffworks.com.)
various amounts of carbohydrates are consumed both during and between
meals.
1.2 Glucose monitoring for diabetes mellitus
In diabetes mellitus, this feedback homeostasis of blood glucose concen-
tration is lost. This results in hyperglycemia and glucose intolerance due
to insulin deficiency, impaired effectiveness of insulin action, or both. In
type 1 diabetes, the autoimmune destruction of the pancreatic beta cells
leads to severe insulin deficiency, which in the absence of insulin replace-
ment, would lead to death because of the inability to assimilate nutrients.
Fortunately, since the discovery of insulin in the early 1920s, patients were
able to survive by injecting insulin themselves two to four times a day. In
Type 2 diabetes, the glycemia regulation is impaired due to a combination
of defective insulin secretion and a reduced insulin sensitivity. It is often
2
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Figure 1.2: Procedure for self-monitoring of blood glucose: a drop of blood
is applied on a test strip inserted on a handheld glucose meter.
associated with obesity, which itself can cause insulin resistance and lead
to chronic high blood glucose levels. Type 2 diabetes is often managed by
increasing exercise, dietary modification and routinely monitoring glucose
levels. However, it may require insulin in case of persistent hyperglycemia.
Diabetes is one of the leading cause of death and disability in the world.
Serious long term complications are related to chronic hyperglycemia, in-
cluding higher risks of heart disease, kidney failure, or blindness [1]. Such
complications were thought to be greatly reduced through stringent per-
sonal control of blood glucose, and since the early 1980s, blood glucose
levels have been self-monitored. The test involves pricking a finger with a
lancet device to obtain a small blood sample, and applying a drop of blood
onto a dry chemical test strip inserted in a handheld meter for determin-
ing the glucose concentration (Fig. 1.2). Self-monitoring of blood glucose
allows the improvement of glycemic control by collecting detailed infor-
mation about blood glucose levels throughout the day. It helps diabetic pa-
tients to adjust their dietary intake, physical activity, and insulin doses in
response to blood glucose values. The effectiveness of self-monitoring was
confirmed by measuring the glycosylated hemoglobin, which is a marker
of metabolic control over the previous 3–4 months. In general, studies sup-
port the evidence that self-monitoring of blood glucose is effective in im-
proving glycemia [2]. The advent of self-monitoring is therefore considered
as a major advance in diabetes management.
Today, millions of diabetics test their blood glucose levels daily, making
3
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Figure 1.3: Glycemia evolution of a diabetic over one day. The green
points represent the points-in-time monitoring obtained with finger-stick
measurements, and the blue curve the real glycemia. (Reprinted from [3].)
glucose the most commonly tested analyte. However, conventional glucose
monitoring is a discontinuous process that tells the patient about blood glu-
cose concentration only at the moment it is performed. The fluctuations
occurring between two measurements are not recorded. As the feedback
homeostasis is lost, rapid fluctuations can occur, particularly after a meal
or after insulin injection (Fig. 1.3). Hypo- and hyperglycemic episodes are
therefore commonly happening in spite of frequent monitoring. Moreover,
to avoid hypoglycemic episodes which could lead to unconsciousness, pa-
tients often regulate their blood glucose above the normal range. As a
consequence, despite intensive insulin therapy, diabetic patients generally
have their level of glycosylated hemoglobin over the normal range. This
is a great concern regarding the long term complications associated with
elevated blood glucose.
1.3 In vivo continuous glucose monitoring
1.3.1 Subcutaneous needle-type glucose sensor
The limitations of intermittent glucose monitoring were early recognized
and a lot of effort was put towards the development of continuous glucose
4
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Figure 1.4: Example of commercially available subcutaneous im-
plantable needle-type glucose sensor (Guardian REAL-Time System from
Medtronic).
meters [4]. In fact, continuous glucose monitoring (CGM) would provide
maximal information about shifting blood glucose levels throughout the
day and would therefore facilitate the making of optimal treatment deci-
sions for the diabetic patient. Moreover, the sensor could be part of an
alarm system to inform the patient about glucose concentrations outside
the normal range, especially in the direction of hypoglycemia. The ultimate
goal would of course be an artificial pancreas, consisting of a closed-loop
insulin delivery system.
In the early 2000s, subcutaneous implantable needle-type glucose sen-
sors became commercially available (Fig. 1.4). Such devices track glucose
levels by measuring the glucose concentration in the interstitial fluid of the
subcutaneous tissue. They are commonly inserted into the subcutaneous
tissue in the abdomen or upper arm. Today, CGM devices are used to bet-
ter understand the glycemia pattern of difficult-to-control diabetes and to
facilitate adjustments in therapy. For instance, the impact of lifestyle mod-
ifications or mealtime insulin bolus changes can be assessed using a CGM
device. This is therefore a very efficient tool for patient education. How-
ever, the limited accuracy is hindering a more routine use of these devices
[5]. In fact, currently available CGM devices require up to four finger-stick
blood glucose measurements per day for calibration. Moreover, they are
5
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not sufficiently accurate to make therapeutic decisions and a finger-stick
blood glucose measurement has always to confirm the CGM value. Finally,
they do not measure the glucose concentration in the whole blood, but in-
stead in the interstitial fluid, which introduces a lag time [5].
As methods for minimally invasive continuous monitoring advance, it
appears likely that CGM devices will eventually become a routine part of
diabetes management. However, in spite of the many impressive break-
throughs in the design and use of glucose biosensors, the promise of tight
diabetes management has not been fulfilled. There are still major chal-
lenges in achieving clinically accurate continuous glycemic monitoring sys-
tems. Undesirable interactions between the surface of the implanted device
and biological medium cause deterioration of the sensor performance upon
implantation and proved to be the major barrier to the development of re-
liable in vivo glucose probes [6].
1.3.2 Limitations of electrochemical devices
The vast majority of glucose sensors used for in vivo applications are based
on electrochemical detection. Basically, the measurement relies on a glu-
cose oxidase (GOx) coated electrode. This enzyme catalyzes a chemical
reaction between glucose and oxygen, which generates an electroactive
product measured by common working electrodes. With such a detec-
tion method, other oxidizable constituents of biological fluids can compro-
mise the selectivity and hence the overall accuracy of measurement [6, 7].
Considerable effort was devoted to minimizing the interference of coex-
isting electroactive compounds. Major improvements were realized by
coating the electrode for minimizing the access of these constituents and
decreasing the operating potential. Oxygen consumption by the oxidase-
based reaction was an other major limitation for in vivo measurements. In
fact, physiological oxygen concentrations are about one order of magnitude
lower than the glucose level. This limitation, known as oxygen deficit, was
addressed by using mass-transport-limiting films for increasing the oxy-
gen/glucose permeability ratio. However, despite these technological im-
provements, challenges for achieving a reliable and accurate in vivo elec-
trochemical sensor remain. In particular, these include long term stability
of the enzyme and transducer, oxygen deficit and surface biofouling (the
adhesion of biomolecules to surfaces) of the electrode.
6
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Figure 1.5: Concept of long term implantable autonomous glucose sensor.
1.3.3 Long term implantable glucose sensor
A minimally invasive, long term implantable glucose sensor would be an
interesting alternative to achieve tight glucose control for diabetic patients.
Such a sensor would be implanted in the subcutaneous tissue and would
wirelessly transmit the glucose measurements to an external handheld de-
vice, like the patient’s smartphone (Fig. 1.5). The signal from the sensor
would be sent to the external device via radiofrequency and the power nec-
essary for the sensor operation would be transmitted via inductive power
telemetry. The wearable patient control unit would display real-time glu-
cose levels updated every few minutes as well as the glucose level trends
based on the past 20–30 minutes. The sensor would be implanted in the
physician’s office using a minimally invasive procedure (using a trocar for
example) and would operate for up to 12 months.
Compared to existing transcutaneous needle-type sensors, a long term
implantable sensor would eliminate the need to wear an external cumber-
some device and to regularly change the needle. Moreover, a stable sensor-
tissue interface would be established, whereas the recent implantation of a
transcutaneous sensor generates a local inflammation. This is expected to
decrease the frequent calibrations generated by a changing local environ-
ment.
However, the development of a long term implantable sensor is a chal-
lenge with many functional requirements. The implantable sensor should
7
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have a very small size allowing minimally invasive implantation. The
detection method and control electronics should therefore allow extreme
miniaturization. In addition, the sensor should operate for up to 12 months
after implantation with infrequent recalibration. This requires a glucose de-
tection method which is stable and reliable for in vivo long term operation.
Finally, the sensor-tissue interface is probably the most critical aspect for
the long term sensor function. After typically 2–3 weeks, the sensor is en-
capsulated by a fibrotic capsule, which significantly hinders the glucose
diffusion and leads to an increased response time. The sensor-tissue in-
terface must therefore be coated with a biocompatible material promoting
neovascularization within the matrix of the coating material.
Despite the considerable effort devoted to the development of an im-
plantable glucose sensor, the technological challenges for long term in vivo
monitoring have not been solved, and to date no product was brought to
commercial realization.
1.4 Critically ill patients monitoring
In critical care, aberrant respiratory, cardiovascular, and other parameters
are generally restored to physiologic levels in the belief that such maneu-
vers would confer a survival benefit. Glucose homeostasis is often dysreg-
ulated in critically ill patients, resulting in hyperglycemia, even those who
have not previously had diabetes. Recently, clinical studies have demon-
strated that maintenance of normoglycemia with intensive insulin therapy
can reduce morbidity and mortality in critically ill patients [8, 9, 10, 11]. It
is hypothesized that hyperglycemia or relative insulin deficiency may con-
fer a predisposition to complications such as severe infections or multiple-
organ failure.
Today, tight blood glucose control are performed in certain intensive
care units (ICU), by taking and analyzing blood samples every 30–60 min-
utes. Several glucose monitoring handheld devices providing quantitative
glucose measurement of capillary, venous and arterial blood are FDA2 ap-
proved for the ICU. However, tight glycemic control increases the nursing
2The Food and Drug Administration (FDA) is an agency within the U.S. Department of
Health and Human Services protecting the public health by assuring the safety, effective-
ness and security of a wide variety of products. In particular, medical devices are regulated
by FDA’s center for Devices and Radiological Health.
8
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workload and its implementation may prove to be a challenge as it requires
a change in practice and an adequate education of the nursing staff. A con-
tinuous glucose sensor would likely facilitate the implementation of tight
blood glucose control, and would also provide alarm signals for impending
glycemic excursions.
Several pilot studies of continuous glucose monitoring and closed-loop
control have been performed using subcutaneous needle-type glucose sen-
sors [12, 13, 14, 15]. However, commercially available CGM devices are not
accurate and reliable enough for implementing a truly closed-loop control,
and blood glucose measurements are still required. Moreover, capillary
blood values obtained by finger stick, or measurements in the interstitial
fluid do not appear to be reliable in the ICU setting [16, 17].
There is therefore a strong need for a continuous glucose sensor mon-
itoring accurately and reliably in arterial blood. In 2008, Edwards Life-
science, a leader in the monitoring of critically ill patients, and DexCom, a
developer of continuous monitoring systems for diabetic patients, entered
into a collaboration agreement to develop a continuous sensor for moni-
toring blood glucose levels for critically ill patients. This emphasizes the
growing interest for tight glycemic monitoring in the ICU. However, there
is currently no commercially available product, which indicates that elec-
trochemical methods encounter difficulties in accurately and reliably mon-
itoring glucose levels in blood.
1.5 Affinity sensing as an alternative method
1.5.1 Advantages of affinity sensing
The development of glucose sensor for in vivo applications that allows for
long term reversibility and stability remains a challenge. In this context,
alternative approaches to overcome the limitation of electrochemical meth-
ods have been investigated. Research groups focused on affinity sens-
ing based on either glucose-specific protein concanavalin A (ConA) [18,
19, 20, 21, 22, 23] or acid boronic-based artificial glucose-specific recep-
tors [24, 25, 26]. Independent of the type of receptor, affinity sensing of-
fers several intrinsic advantages for in vivo monitoring. The absence of an
electrode-based system eliminates its related issues, like potential interfer-
9
Chapter 1. Introduction
ences of electroactive components or the dependence upon oxygen tension.
Furthermore, the binding reaction in affinity-based sensors is equilibrium
driven, resulting in a signal sensitivity that is independent on the rate of
glucose diffusion into the sensor. This is an advantage when compared
to electroenzymatic sensors, which consume glucose and therefore depend
on its diffusion rate. In particular, biofouling which degrades the sensitiv-
ity and stability of electrochemical measurements should only increase the
response time of the affinity sensor. For these reasons, investigations on
affinity binding sensors have been undertaken using various technologies,
such as fluorescence [20, 21, 22, 25] or viscosity-based [19, 27, 28] princi-
ples. In particular, Roche (Disetronic) worked on the development of a
subcutaneous implantable needle-type glucose sensor relying on monitor-
ing glucose-induced changes in the viscosity associated with binding to
ConA [29, 30].
1.5.2 A novel viscometric affinity biosensor
We propose a novel chemico-mechanical concept which aims at detecting
viscosity changes of a solution featuring a selective affinity for glucose. The
innovation relies in the viscosity detection method, which is based on the
measurement of the flow resistance of a microchannel upon piezoelectric
diaphragm actuation. This piezoelectric-based measurement should pro-
vide a very accurate and low-power viscosity detection controlled with ba-
sic electronics. In addition, the sensor topology would allow its realization
using microfabrication technology, thus allowing the required miniaturiza-
tion. These characteristics, combined with the intrinsic advantages of affin-
ity sensing for in vivo monitoring, make this sensor particularly well suited
for long term implantable applications. Beside that, microfabrication tech-
nology may allow batch manufacturing, and therefore disposable sensors
for in vivo and ex vivo applications could also be envisioned.
In this thesis, after a brief state-of-the-art of glucose measuring tech-
nologies, the sensor principle and modeling are presented in detail, in-
cluding the viscosity detection method, the glucose sensitive fluid and the
sensor-body interface. The glucose sensor demonstrator and the experi-
mental test setup are then presented, followed by the viscosity detection
method and model validation using viscosity reference standards. Next,
the glucose sensor demonstrator was extensively characterized in isotonic
10
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saline solution of varying glucose concentrations, investigating the sensor
reversibility, reproducibility and stability. The long term performance of
the demonstrator was further evaluated regarding its potential application
as a long term implantable sensor. Finally, the glucose sensor demonstrator
was assessed in human blood serum and plasma for checking its adequacy
to detect glucose in biological fluids. Special attention was paid to biofoul-
ing of the sensor-body interface and to potential interferences from other
biomolecules present in blood.
11
Chapter 1. Introduction
12
Chapter 2
Glucose measuring
technologies
2.1 First glucose sensors
The initial dominant detection technology for glucose sensors was based
on a reflectometer invented by Anton Clemens in 1971, whose work led to
the launch of the first blood glucose measurement system, the Ames Re-
flectance Meter. The intrument measured the reflected light from a strip
covered with a chemical reagent whose color was changing with the addi-
tion of a drop of blood. Even if the original Ames Reflectance Meter was
large and expensive, it was a success and led to a variety of products.
In 1975, Yellow Spring Company (YSI) launched the first commercial
electrochemical glucose analyzer for direct measurement of glucose in 25 µL
whole blood samples. The measurement relied on the enzyme glucose ox-
idase (GOx) which catalyzes a reaction between glucose and oxygen pro-
ducing gluconic acid and hydrogen peroxide (H2O2):
glucose + O2
GOx−−−−→ gluconic acid + H2O2
In this original device, glucose oxidase was immobilized between two
membrane layers. An outer polycarbonate membrane confined the enzyme
whilst allowing glucose to diffuse. It also reduced the interferences by pre-
venting large biomolecules present in the blood from entering into the de-
vice. In presence of the enzyme, glucose was oxidized, producing hydro-
gen peroxide. This latter diffused through a cellulose acetate membrane
13
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Figure 2.1: Sequence of events that occur in mediator-based electrochemi-
cal glucose sensors. (Reprinted from [6].)
and was amperometrically measured by a platinum electrode. The second
membrane acted as a further size exclusion barrier preventing many other
electroactive compounds from reaching the electrode surface. Since then,
the YSI device and its successors have become a standard for clinical diag-
nostics used in many hospitals and laboratories.
2.2 Electrochemical test strips
During the 1980s, considerable efforts were devoted to the development
of electrochemical glucose sensors for home testing. Oxygen was replaced
with a nonphysiological (synthetic) electron acceptor for catalyzing the glu-
cose oxidation (Fig. 2.1). This facilitated the electrons transfer to the elec-
trode surface, which no longer depended on the local oxygen concentra-
tion. Moreover, this allowed to decrease the operating potential, thus re-
ducing the interferences from other electroactive compounds and conse-
quently enhancing the sensor performance. The electrochemical technol-
ogy was further adapted to disposable test strips by using screen-printing
technology which allowed inexpensive and reproducible test strips man-
ufacturing. Screen-printing was widely used in the electronics industry,
allowing the deposition of patterned thick-films in a simple and rapid way.
The screen-printing technology involves printing patterns of conductors
and insulators onto the surface of planar (plastic, ceramic, metal) substrates
based on pressing the corresponding inks through a patterned mask. This
process was one of the major reasons for the commercial success of electro-
chemical glucose sensors.
In 1987, Medisense launched the first glucose sensor for self-monitoring
of blood glucose based on electrochemical test strips. Glucose was amper-
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Figure 2.2: Cross section of a commercial strip for self-testing of blood glu-
cose (based on the Precision biosensor manufactured by Abbott Inc.): (A)
electrode system; (B) hydrophobic layer (drawing the blood). (Reprinted
from [6].)
ometrically measured using a GOx electrode and a ferrocene mediator [31].
Ferrocene and its derivatives were in fact shown to rapidly shuttle electrons
from GOx to electrodes [32]. Various improvements have been incorpo-
rated since the launch of the original device, but the concept has remained
unaffected. Commercial blood glucose self-testing meters commonly rely
on the use of ferricyanide or ferrocene mediators [6]. A strip is typically a
plastic substrate containing the printed working and reference electrodes,
with the working one coated with an enzyme, a redox mediator and other
reagents (Fig. 2.2). A small volume capillary chamber (∼1 µL) is formed
over the electrodes by means of an adhesive spacer and a cover layer. In
addition, various membranes are often incorporated in the test strips to
separate the blood cells and minimize interferences for other biomolecules.
Today, over 40 different commercial strips and pocket-size monitors
have been introduced for self-testing of blood glucose [33]. However, over
90% of the market is dominated by four major diagnostics compagnies,
including Roche Diagnostics, Abott, Bayer and Lifescan (Table 2.1). The re-
cent glucose meters utilize capillary fill which allow sampling small blood
volumes (0.3–4 µl), thus allowing to decrease the needle size and to reduce
the pain associated with finger pricking. In addition to fast response (5–30
s), good accuracy (5–10% rms error compared to laboratory standards) and
automatic fill detection, modern glucose meters have extended memory ca-
pacity, automatically storing results along with times and dates. Some de-
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Table 2.1: Characteristics of leading commercial blood glucose self-testing
meters.
Accu-Chek Performa FreeStyle Lite ContourTS
Company Roche diagnostics Abbott Bayer
Sample size 0.6 µL 0.3 µL 0.6 µL
Test time 5 s 5 s 8 s
Memory 500 tests 450 tests 250 tests
Operating temp. 14–40˚C 10–50˚C 5–45˚C
vices have also features such as computer downloading capabilities which,
combined with data management systems, allow to quickly review and an-
alyze the results. Test strips are produced in high volume (∼6 billion total
electrochemical strips/years in 2007), at high manufacturing yield, low cost
(<5 cents/test strip), with a defect rate of less than 0.1% [7]. Overall, the at-
tractive performance of modern blood glucose monitors reflects significant
technological advances along with major fundamental developments.
2.3 Continuous glucose monitoring
2.3.1 Major commercial developments
The development of continuous glucose sensors was initiated with the hope
that this new glucose measurement tool would enable significant improve-
ments in diabetes management. The early 1980s saw the appearance of an
important symposium on potentially implantable glucose sensors, which
included several important contributions from many of the leaders in the
field [34]. However, developing reliable in vivo glucose sensors was an
enormous technical challenge, and this is only in 1996 that the first contin-
uous glucose sensor (MiniMed, Northridge, CA), based on a subcutaneous
amperometric electrode, moved from the laboratory bench to clinical trials.
The MiniMed CGMS was FDA approved in 1999 and became the first com-
mercial CGM system [35, 36]. However, this system was not FDA approved
to provide real-time glucose measurements, and thus the results had to be
downloaded in a physician’s office. It will be in 2005 that a continuous glu-
cose sensor displaying real-time glucose values, the Medtronic Guardian
RT system, was approved by the FDA [37]. Following a 2 hours warm-up
period, this system displays updated glucose values every 5 minutes and
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sounds an alarm when glucose levels become too high or too low. Since
then, two other companies received FDA approval for their real-time CGM
systems based on similar electrochemical technologies. The STS glucose
monitor from DexCom, Inc. (San Diego, CA) and the FreeStyle Navigator
glucose monitor from Abbott Diabetes Care (Alameda, CA) were respec-
tively approved in 2006 and 2008.
An alternative to implanted electrodes is to use microdialysis as an in-
terface between the body and the biosensor. In 2002, Menarini Diagnos-
tics (Florence, Italy) received the CE1 approval and since then, commercial-
izes the GlucoDay, a glucose monitor based on a microdialysis technique.
Clinical trials showed good correlation with blood glucose measurements
[38, 39, 40]. However, it was not approved for real-time monitoring and
is therefore used by professionals for the retrospective analysis of glucose
trends. A hollow dialysis membrane (in regenerated cellulose) is subcuta-
neously inserted and perfused with an isotonic fluid, in which glucose from
the interstitial fluid diffuses. The isotonic fluid is pumped (with a flow rate
of 15–100 µL/min) outside the body, where the glucose is detected using
an amperometric enzyme electrode [41, 42]. As the electrode is outside the
body, this eliminates the issue of subcutaneous oxygen deficit. This is also
advantageous regarding biofouling which cannot interfere with the mea-
surements. However, as the isotonic fluid has to be pumped to the sensor,
a lag time into the measurements is introduced, which could be of concern
regarding real-time monitoring.
Beside the currently available needle-type CGM devices, alternative de-
tection methods led to commercial developments. The GlucoWatch Biog-
rapher developed by Cygnus, Inc. (Redwood, CA), was approved by the
FDA in 2001 for real-time display of glucose values. It employed reverse
iontophoresis, in which a small current is applied and brings subcutaneous
fluid through the skin by attraction of ions [43, 44]. The extracted fluid,
which is characterized by a glucose concentration proportional to the sub-
cutaneous fluid, is collected in a hydrogel pad and the glucose is detected
electrochemically. The device is worn like a wristwatch and provides glu-
cose measurements every 10 minutes. Despite the FDA approval and clinial
trials [45, 46], it was never widely accepted in the market-place. Sweating,
1"Conformité Européenne", certification required for medical devices in the European
Union.
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rapid temperature changes, cold skin or excess movement precluded glu-
cose measurements and led to frequent skipped readings. In 2007, Animas
Corp. which purchased Cygnus one year earlier, decided therefore to stop
selling the GlucoWatch Biographer system.
Unlike all the other continuous glucose monitoring devices, the Pendra
developed by Pendragon Medical Ltd. (Zurich, Switzerland), was truly
noninvasive. It operates by impedance spectroscopy, generating a small
electromagnetic field across the skin in the frequency range of 1–200 MHz.
Sodium and potassium transport over the erythrocyte membrane, which
is related to changes in glucose levels, results in a change of impedance
detected with the Pendra device. Initial evaluations of the device were
promising [47, 48], and the Pendra was CE approved for the European
market in 2004. However, post-market evaluations indicated poor accu-
racy and the device also suffered from unsuitability for large number of
patients due to strong varying skin and subcutaneous properties [49]. Like
most non-invasive methods, the changes in impedance measured by the
device was likely suffering from interferences due to the complexity of bi-
ological tissues. As a consequence, the device was withdrawn from com-
mercial distribution and Pendragon Medical filed for bankruptcy in 2005.
2.3.2 Subcutaneous amperometric technology
All commercially available real-time continuous glucose sensors rely on a
subcutaneous glucose oxidase (GOx) electrode, a technology which bene-
fited from the previous developments of home blood glucose monitors. In
electrochemical test strips, the enzyme and mediator are typically applied
to the working electrode as a solution and deposited by solvent evapora-
tion. However, such a straightforward technique was not compatible with
continuous in vivo monitoring, as the enzyme and mediator would dissolve
in the subcutaneous fluid and diffuse away form the electrode. For a sensor
to successfully operates in vivo, the enzyme and mediator have therefore
to be immobilized onto the electrode surface. A variety of techniques for
immobilizing enzymes exists, like adsorption onto insoluble particles, co-
valent linking to an insoluble polymer matrix, or enzyme entrapment with
a porous polymer membrane. However, the enzyme immobilization re-
mains a key factor for in vivo continuous monitoring and the methods used
in commercial sensors are often proprietary and protected as trade secrets.
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Figure 2.3: Commercially available transcutaneous sensors. (A) FreeStyle
Navigator; (B) Dexcom STS; (C) Guardian RT. (Reprinted from [7].)
Transcutaneous amperometric sensors consist of a thin, sub-1 mm di-
ameter, flexible sensor having a working electrode with an immobilized
enzyme (GOx) and an Ag/AgCl reference electrode (Fig. 2.3) [7]. The elec-
trooxidation of glucose is mediated by either oxygen, or by an immobi-
lized redox mediator. Due to potential leaching and toxicity of the media-
tor, most in vivo devices (Guardian RT, Dexcom STS) are mediatorless [50].
However, when using oxygen as electron acceptor, the low physiological
oxygen concentration is an issue regarding to the electrochemical reaction.
Both sensors addressed the oxygen deficit limitation using a block copoly-
mer membrane, which consists of a hydrophobic polymer highly perme-
able to oxygen and impermeable to water and thus glucose, and of a hy-
drophilic polymer enabling glucose flux. By varying the ratio of the two
polymers, the oxygen and glucose flux are adjusted to an optimal value for
the redox reaction.
The last approved device (FreeStyle Navigator) is based on an alterna-
tive mediator substituting for oxygen, using the enzyme wiring technol-
ogy. The enzyme is wired to the electrode surface with a long hydrophilic
polymer backbone having a dense array of covalently linked redox poly-
mers. An advantage of the wired enzyme is a lower operating potential,
thus reducing the electroactive interferences. However, although the wired
enzyme is not subject to the subcutaneous oxygen deficit, the enzyme con-
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Table 2.2: Characteristics of the three FDA approved real-time continuous
monitoring devices [51].
Guardian RT DexCom STS-7 FreeStyle Navigator
Company Medtronic DexCom Abbott
FDA Approval 2005 2006 2008
Enzyme GOx GOx GOx
Mediator Oxygen Oxygen Redox mediator
Life time 3 days 7 days 5 days
Calibration Every 12h Every 12h At 10, 12, 24 and 72h
Test freq. 5 min 5 min 1 min
centration that can be immobilized on the surface of an electrode is low
and saturated at very low glucose levels. A glucose limiting membrane is
therefore still required.
2.3.3 Performance of commercial devices
The three commercial real-time devices have similar characteristics (Ta-
ble 2.2) [51]. Initially, a suitable break-in period of 1–10 hours has to be
observed, both to equilibrate the sensor with its tissue-environment and to
normalize the insertion-wound perturbed site. After the initial stabiliza-
tion period, the sensor has to be calibrated because of the variability of
the subcutaneous environment. The calibration procedure is performed by
testing the capillary blood glucose concentration using a glucose test strip.
The in vivo calibration process has to be repeated during the implantation
to correct the sensor output drift, due to the ever-changing wound heal-
ing environment and biofouling of the system. The glucose concentration
is measured and displayed in real-time every 1–5 minutes, and depending
on the model, the subcutaneous sensor has to be replaced every 3–7 days.
Finally, the precision of CGM devices is very much dependent on the cal-
ibration. In fact, as there is a lag time between the blood and interstitial
fluid glucose concentration, a calibration performed while the glycemia is
fluctuating results in poor precision.
The frequent calibrations and the lack of accuracy and reliability are the
major drawbacks of all approved continuous sensors [52]. At low glucose
(below 80 mg/dL), all of the sensors have lower accuracy than they do at
higher levels [53], which is critical because the low regions are by far the
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most important. However, these sensors are accurately and reproducibly
measuring glucose on the bench with no need for calibration, which indi-
cates that the main source of sensor inaccuracy comes from the biological
environment in which the sensor is placed. In particular, the high vari-
ability of glucose and oxygen in the wound healing site is thought to be
responsible for calibration changes [7]. Biofouling of the device is also
likely changing the rate-dependent signal of the enzyme electrode. Now
that the fundamental measurement principle has been demonstrated, im-
provements in accuracy and reliability will likely be achieved by ingenious
technological and manufacturing improvements. A better understanding
of the factors causing sensitivity-variation would also help in improving in
vivo sensor performance.
2.4 Affinity sensing technology
2.4.1 Fluorescence affinity sensors
Due to the problems encountered by the amperometric enzyme electrode
for in vivo sensing, new approaches to glucose sensing have been actively
explored. Amongst these, affinity sensing received particular attention as
it is thought to offer several intrinsic advantages for in vivo monitoring.
The affinity detection principle was inspired by immunoassays developed
in the 1950s, which consist in measuring the concentration of an antigen in
blood using its affinity for a specific antibody. In 1982, early developments
on affinity sensing were reported by Schultz et al., based on the competi-
tive binding of glucose and dextran with a glucose-specific binding protein,
Concanavalin A (ConA) [18]. The specific affinity of ConA with polysac-
charides was previously investigated by Goldstein et al., which reported
that ConA was interacting with the nonreducing chain ends of the dex-
tran molecule [54]. In the sensor described by Schultz et al., ConA was
immobilized on the inside surface of a hollow dialysis fiber containing
a high-molecular-weight dextran labeled with fluorescein isothiocyanate
(FITC) (Fig. 2.4). The molecular weight cutoff of the dialysis fiber was low
enough to completely retain dextran within the fiber lumen while glucose
was freely permeating through the membrane. Glucose entering from the
external medium displaced dextran from ConA and increased the fluores-
21
Chapter 2. Glucose measuring technologies
Immobilized 
Concanavalin A
Fluorocrome-labeled 
dextran Hollow fiber membrane
Optical fiber
Excitation
Emission
Glucose
Figure 2.4: Schematic view of the original fluorescence affinity sensor
based on a hollow dialysis fiber proposed by Schultz et al. in 1982 [18].
cence intensity in the lumen, which was recorded using an optical fiber.
Preliminary tests of the sensor indicated the feasibility of the approach.
This concept was later adapted by the same laboratory so that mea-
surements were based on Fluorescence Resonance Energy Transfer (FRET)
[55]. FRET relies on the distance-dependent transfer of energy from a flu-
orescent molecule which absorbs the incident radiation (donor molecule)
to an other fluorescent molecule to which the energy is subsequently trans-
ferred (acceptor molecule). The transfer of energy leads to a reduction in
the donor’s fluorescence intensity and an increase in the acceptor’s emis-
sion intensity. In this new fiber-optic sensor, FITC-dextran and rhodamine-
ConA were respectively the donor and acceptor molecules. When glucose
is added to the solution, FITC-dextran and rhodamine-ConA move further
apart, which lead to a decrease in energy transfert and consequently an
increase in the donor fluorescence. The glucose concentration is therefore
directly related to the FITC fluorescence. The working range of the solu-
tion was adjuted to physiological glucose concentration with a good sen-
sitivity up to 200 mg/dL. However, the stability of the solution was quite
poor, ConA precipitating and forming aggregates over periods of hours.
Chemical procedures were subsequently developed to prevent the ConA
aggregation and the solution was shown to be stable over several days
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[56]. Moreover, the ratio ConA-dextran was optimized to achieve glucose
detection up to 1600 mg/dL. The sensor was further improved by using
FITC-dextran, rhodamine-dextran and unmodified ConA in an attempt to
avoid chemical modifications of the protein which are time-consuming and
can affect its binding activity [57]. The sensor stability was also enhanced,
showing a good measurable fluorescence signal over 11 days.
Ballerstadt and co-workers have further investigated various concept
of fluorescence affinity sensors. In 2000, to avoid the risk of bacterial in-
fection related to needle-type sensors, they proposed a concept of subcuta-
neous implantation relying on the illumination and fluorescence measure-
ment through the skin [21]. To ensure that the fluorescence emission was
sufficiently high to be measurable through skin tissue, they increased the
fluorescence response intensity by a factor 50, by using immobilized pen-
dant glucose moities inside Sephadex beads. The long term stability of this
sensor was investigated by continuously cycling glucose test solutions dur-
ing 4 months, showing a decrease in fluorescence of 25% per month [20].
Aqueous ConA was considered the weakest link due to its involvement
in precipitation reactions in response to protein-to-protein aggregation and
protein/dextran-induced precipitation reactions [58, 57]. In an attempt to
prevent these adverse precipitation reactions, and therefore increase the
stability and lifetime of the sensor, ConA was immobilized within a macro-
porous bead matrix, which led to a remarkable long term stability of the
sensor (6 months) [59]. They further successfully demonstrated in vivo per-
formance of an implanted fluorescence affinity sensor over more than 16
days in a rodent model [60].
In conclusion, the technical feasibility of fluorescence affinity sensors
has been clearly demonstrated. Significant improvements to the overall
performance of the sensor have been made since the concept introduction
in 1982. However, long term stability remains a challenge, due to inferior
ConA stability and inadequate photostability of fluorescent dyes. There-
fore, the search for an optimal sensor configuration that fulfills practical
requirements such as a chemically and optically stable signal continues.
2.4.2 Viscosity-dependent affinity sensors
The change in viscosity of a glucose sensitive fluid was also extensively
investigated as an alternative method to fluorescence for the signal trans-
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Figure 2.5: GlucOnline device prototype from Disetronic (left) and
schematic view of the measuring principle (right): (1) reservoir and pump;
(2) microdialysis through the semi-permeable membrane; (3) subcutaneous
tissue; (4) collecting vessel. The viscosity is measured using the two pres-
sure sensors η1 and η2.
duction of affinity sensors. In 1994, Ballerstadt and Ehwald demonstrated
this variant by filling a hollow fibre of regenerated cellulose with a solution
of dextran and ConA [19]. Air pressure pulses were used for generating os-
cillations of the fluid, the amplitude of which was measured with an ocular
micrometer. They further investigated the viscosity response of different
formulations of sensitive fluid based on dextran and ConA [61]. They sug-
gested that high-molecular-weight dextran combined with a low value of
basic viscosity were suitable regarding both the absolute and relative sen-
sitivity. Next, the effect of frequency and shear stress on the rheological
properties of the sensitive fluid was also assessed with a view to the sensor
design [62].
The same laboratory, in collaboration with Disetronic Medical Systems
(Burgdorf, Switzerland), developed a transcutaneous needle-type glucose
sensor based on this viscometric principle [29]. The needle encloses a dialy-
sis hollow fiber through which the sensitive fluid is continuously pumped
with low rate (∼5 µL/h). The viscosity is determined by measuring the
pressure difference created by the flow at both ends of the fiber using two
pressure sensors. The viscometric sensor showed a linear and stable depen-
dence on the glucose concentration, with a response time of 5–10 min. This
device was further developed by Disetronic under the trade name Gluc-
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Figure 2.6: Schematic cross view of the MEMS viscometric glucose sensor
proposed by Zhao et al. Dimensions indicated in micrometer. (Reprinted
from [28].)
Online (Fig. 2.5). In 2004, the performance of the sensor was evaluated in
a clinical pilot study on twelve type 1 diabetic patients [30]. An error grid
analysis of the results showed that 98.9% of the values were within the clin-
ically acceptable zone, but the residual values were clinically unacceptable.
Disetronic was acquired by Roche in 2003, which further sold the GlucOn-
line project to Sensile Medical. This company was not able to enter the
market with the GlucOnline concept.
The recent advance of microfabrication technolgies, allowing batch fab-
rication of miniaturized devices, led to the development of new sensors
based on a viscometric sensitive fluid. In 2007, Zhao et al. reported a
MEMS viscometric sensor based on a magnetically-driven vibrating mi-
crocantilever located in a microfluidic chamber filled with a dextran-ConA
sensitive fluid [28]. The cantilever was realized by patterning a layer of
SU-8, a commonly used epoxy-based photoresist, and the subsequent de-
position of permalloy thin film strips at its free end (Fig. 2.6). The cantilever
was actuated by applying a magnetic field to the permalloy strips, which
induced a flow of the solution. The damping effect of the flow on the can-
tilever vibration, which was directly dependent on the solution viscosity,
was recorded using an optical system. The glucose dependence of the can-
tilever vibration was demonstrated, although they did not show continu-
ous and reversible measurement. They further developed a biocompatible
boronic acid based polymeric sensitive fluid in order to address stability
issues related to the dextran-ConA solution [26]. The device was also im-
proved by fabricating the microcantilever from Parylene, a biocompatible
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Figure 2.7: Measurement principle of the glucose sensor based on a con-
centric rotational microviscometer developed by Kuenzi et al. (Reprinted
from [3].)
soft polymer, which decreased the resonance frequency of the cantilever to
∼30 Hz [27]. Short term (20 hours) continuous reversible measurements
were reported. The last variant of the sensor consisted of a Parylene di-
aphragm, whose vibration was measured capacitively [63].
Since 2003, our laboratory has been investigating viscometric affinity
sensors for continuous glucose monitoring. A concentric rotational micro-
viscometer was developed and extensively characterized using viscosity
reference standards [64]. A magnetic cylinder was actuated by a rotational
magnetic field, and its angular position was recorded with Hall effect sen-
sors (Fig. 2.7). The viscosity was measured by the viscous friction pro-
duced by the fluid on the rotating magnet. Although this measurement
principle had a high accuracy, only few successful reversible glucose mea-
surements were obtained [65]. Various low viscosity ConA-dextran solu-
tions were also investigated using a glass Ubbelohde viscometer combined
to a camera read-out [66]. The results showed that low-viscous mixtures,
down to 5 mPas, are well suited for glycemic sensing applications. Further
work studied the selective interface between the sensitive fluid and the an-
alyzed solution, which has to retain dextran and ConA whilst being per-
meable to glucose [3]. Glucose diffusion and ConA retention properties of
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nanoporous alumina membranes and nanoporous polyethylene films were
characterized. A good ConA retention was achieved by coating 20 nm
pores alumina membranes with poly(poly(ethylene glycol) methacrylate)
(PPEGMA) brushes.
This work is a continuation of the efforts devoted to the development
of a viscometric affinity sensor for continuous glucose monitoring. In an
attempt to overcome the limitations encountered with the previous device,
possibly due to the high shear stress generated by the high rotational speed
of the rotor, a novel viscosity detection principle was investigated. This de-
tection principle should provide a simple, accurate and low-power viscos-
ity measurement.
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Chapter 3
Sensor principle and
modeling
3.1 Introduction
Presently, continuous glucose monitoring devices require frequent calibra-
tion and are lacking accuracy and reliability. They are based on electro-
chemical detection, which is strongly affected by the biological environ-
ment in which the sensor is placed. The development of clinically accurate
continuous glucose sensors remains therefore a challenge. In this context,
we propose an alternative method, based on affinity sensing, which aims
at detecting viscosity changes of a solution with a selective affinity for glu-
cose. The innovation relies in the viscosity detection method, based on
an induced liquid flow in a microchannel upon piezoelectric diaphragm
actuation. The sensitive fluid is based on the competitive binding of glu-
cose and dextran with a glucose-specific binding protein, Concanavalin A
(ConA). The sensitive fluid is very selective to glucose due to the properties
of ConA, and particularly sensitive at low glucose concentration, which is
crucial to prevent hypoglycemia.
Basically, the sensor is filled with the sensitive fluid, which is confined
by a semi-permeable membrane completely retaining dextran and ConA
within the sensor whilst allowing glucose permeation through the mem-
brane (Fig. 3.1). The sensor includes both an actuating and a sensing piezo-
electric diaphragm as well as a flow-resistive microchannel. In operation,
the actuating diaphragm generates a flow through the microchannel which
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Figure 3.1: Sensor measurement principle: glucose diffuses through a
nanoporous membrane in the sensitive fluid, the viscosity of which is mea-
sured by inducing a flow into a microchannel.
is recorded by the sensing diaphragm, while the microchannel exhibits a
resistance to the flow which depends upon the viscosity.
This chapter presents in detail the three core technologies of the sensor:
the sensitive fluid, the viscosity sensing principle and the semi-permeable
membrane. The sensor modeling is also exposed to provide a better under-
standing of the principles involved in this glucose detection.
3.2 Sensitive fluid
3.2.1 Sensing principle
The sensitive fluid used within the sensor is the key element for glucose
detection. This is based on the competitive affinity of two saccharides,
namely glucose and dextran, to a specific saccharide-binding protein, Con-
canavalin A. The sensing principle was first demonstrated by optical mea-
surement of glucose concentration using fluorescence-labelled dextran [18],
and then from the change in the viscosity of an aqueous blend of dex-
tran and ConA [19]. This competitive affinity process was shown to be
reversible and highly sensitive.
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Figure 3.2: Principle of the glucose sensitive fluid: competitive binding of
glucose and dextran on ConA in the case of low and high glucose concen-
trations.
This viscosity variation of a sensitive fluid using a high-molecular-wei-
ght dextran is actually the core of our sensor. At low glucose concentration,
dextran molecules are cross-linked by binding to ConA, forming a viscous
solution (Fig. 3.2). Next, when the glucose concentration increases, dex-
tran molecules are partially replaced by glucose ones at the binding sites of
ConA. As a result, the network ConA-dextran is weakened and the viscos-
ity of the sensing solution decreases.
3.2.2 Rheological properties
The viscosity variations are especially strong in the human glycemic range
(2–30 mM glucose). Indeed, changes in viscosity as high as one order of
magnitude in the physiological relevant range were reported [66]. The sen-
sitive fluid viscosity can also be tailored for the sensor of interest by modu-
lating the proportions of dextran and ConA. We chose a low viscosity sen-
sitive fluid which was characterized using a standard capillary viscometer
(Fig. 3.3). It is worth noticing that the sensitivity of the fluid is particu-
larly high in the hypoglycaemic range (2–4 mM), whereas it decreases in
the hyperglycaemic range (7–30 mM). High accuracy in hypoglycaemic re-
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Figure 3.3: Characteristics of the low viscosity sensitive fluid used within
the sensor. (Data from [3].)
gion is mandatory to make this sensitive fluid particularly well suited for
patient monitoring. Beside that, the sensitive fluid viscosity is highly tem-
perature dependent. When raising the temperature from 25 to 37˚C, the
sensitive fluid viscosity decreases on average by 38%. This dependance
should therefore be taken into account through calibration when working
in physiological conditions.
3.2.3 Concanavalin A properties
The affinity of ConA for glucose, mannose and their polysaccharides was
firstly described by Goldstein et al. [54], and since then, has been exten-
sively studied. The ConA monomer was reported to be a globular protein
of overall dimensions 42× 40× 39 Å [67]. In solution, ConA appears as
dimer and tetramer configurations (two or four identical subunits) depend-
ing on pH. Below a pH of 5.5, ConA exists as a dimer, and for a pH rang-
ing from 5.5–7.0, ConA is at an equilibrium state of dimer-tetramer [68].
At pH values higher than 7.0 the tetramer configuration is highly prevail-
ing although some dimers seem to remain [69]. Each subunit of ConA has
one specific carbohydrate-binding site [70], which implies that four bind-
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ing sites are present in tetramer configuration. ConA dimer and tetramer
have respectively a molecular weight of 52 and 104 kDa, and their hydro-
dynamic radiuses are respectively 3.3 and 4.4 nm [71].
The glucose binding site of ConA needs to be activated with two metal
ions per monomer. When two ions are trapped, the protein undergoes a
conformational change, forming a so-called locked form, which increases
its affinity for glucose by a factor 1000 [72]. Several transition metals can
bind the two binding sites of ConA, the most stable choice being Mn2+
and Ca2+. The average concentration of Ca2+ in blood is 1.18 mM whereas
Mn2+ only appears as a trace element. Calcium can also be used to activate
the two binding sites, which has the advantage to be closer to in vivo condi-
tions. However, the occurrence of precipitation after a substantial time was
reported when using only Ca2+ [73]. Moreover, a high energy barrier sepa-
rates the two conformations of ConA [74], the locked form should therefore
be stable even in absence of Mn2+ in the measured fluid. As a result, we
selected the most stable configuration (Mn2+ and Ca2+).
ConA has been associated with a variety of toxicological effects in cell
cultures and animals, which may be of concern regarding the implantation
in human for in vivo glucose monitoring [75, 76, 77]. However, the majority
of adverse biological effects observed in animals are the result of the ad-
ministration of large doses of ConA. The small amount of ConA used in
most glucose sensors (10 to 100 times less than dosage tested on animals)
suggests that there would be little or no health risk associated with the sen-
sor rupture [78].
3.3 Viscosity sensing principle
Basically, viscosity is obtained from the relationship between pressure and
flow when the sensitive fluid goes through a channel. The sensor com-
prises two microchambers filled with the sensitive fluid that communi-
cate through a microchannel and a rigid nanoporous semi-permeable mem-
brane (Fig. 3.4). This membrane has two roles: it confines the sensitive fluid
inside the sensor (large molecules cannot go through) and ensures that the
glucose can pass through, meaning that the concentration in the sensor and
in the liquid should be the same. Each chamber is composed of a flexible
piezoelectric diaphragm which whether deflects under voltage (actuating
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Actuating diaphragm Sensing diaphragm
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Sensitive fluid
Microchannel
Figure 3.4: Schematic cross view of the glucose sensor.
diaphragm) or generates a voltage under some pressure load (sensing di-
aphragm).
These actuating and sensing piezoelectric diaphragms together with the
microchannel are the basis for viscosity detection. When a voltage is ap-
plied on the actuating piezoelectric diaphragm, the latter deflects and tends
to generate a flow through the microchannel. Due to its small section, the
microchannel exhibits a resistance to the flow which depends on the fluid
viscosity. Next, the flow through the microchannel is recorded using the
voltage induced by the sensing piezoelectric diaphragm deflection.
Both transient and harmonic electric signals can be used to actuate the
diaphragm (Fig. 3.5). The way viscosity is measured will depend on these
waveforms. In transient mode, a constant voltage is suddenly applied to
the actuating diaphragm for a given time, and then it is switched off. These
states generate a strain in the piezoelectric membrane that in turn will cre-
ate some pressure in the fluid. Due to its small cross section, the microchan-
nel exhibits a resistance to the flow which depends upon the viscosity of
the sensitive fluid. The system is characterized by a relaxation time that
depends upon the viscosity of the sensitive fluid: the more viscous the sen-
sitive fluid, the larger the relaxation time.
Conversely, under harmonic operation, a sinusoidal voltage is applied
on the actuating diaphragm. This generates an alternative flow inside the
microchannel which in turn generates a sinusoidal deflection and induced
voltage of the sensing diaphragm. Since the amplitude and the phase shift
between the applied and induced piezoelectric voltages characterises the
viscosity, we have a simple tool to assess the fluid characteristics: the more
viscous the sensitive fluid, the smaller the deflection and the larger the
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Figure 3.5: Description of the measurement methods for viscosity detec-
tion.
phase shift. In particular, we choose to measure the phase shift between
0 to 90 degrees, which revealed to be an accurate and robust measurement.
3.4 Semi-permeable membrane
3.4.1 Function and requirements
The role of the semi-permeable membrane is to retain the essential mo-
lecules of the sensitive fluid (ConA and dextran) inside the sensor whilst
allowing glucose to diffuse freely in and out. For maintaining the rheo-
logical properties of the sensitive fluid constant, the semi-permeable mem-
brane has also to prevent some of the biological fluid macromolecules (like
peptides and proteins) to penetrate into the sensor. The main constituent
molecules of the sensitive fluid and of a typical biological fluid (intersti-
tial fluid) are sketched in Fig. 3.6. In particular, there may be glycosy-
lated molecules which could competitively interfere with the glucose mea-
surement. The semi-permeable membrane has therefore to act as a size-
selective interface, allowing only the diffusion of molecules of size compa-
rable to glucose. In addition, the interface material has to be biocompatible
and has to minimize biofouling by preventing the non-specific adhesion of
biomolecules.
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Figure 3.6: Illutration of the relative size of the molecules that the mem-
brane has to select. MW is the molecular weight in Dalton. (Reprinted from
[3].)
For small molecules like glucose, the intrinsic selectivity of the mem-
brane is determined by the pore size distribution which defines the mem-
brane molecular weight cut-off (MWCO). For larger biomolecules such as
proteins, polymers or peptides, the molecule dimensions depend on the
three-dimensional structure which itself depends on the chemical environ-
ment. When dealing with complex biomolecules, the selectivity of a mem-
brane is therefore more likely to be compared by the Stokes radius1 than the
MWCO. In addition, the effective radius of a protein in the context of mem-
brane separation can be considerably larger than the Stokes radius due to
the presence of a diffuse ion cloud that surrounds the charged protein in
aqueous solution [79]. For the size-selectivity to act correctly, one could
simply choose a membrane with pores much smaller than the dimensions
of the molecules to be retained. However, the size difference between glu-
1The Stokes radius, or hydrodynamic radius, is the radius of a hypothetical hard sphere
that diffuses at the same rate as the molecule. It is indicative of the apparent size of the
molecule, including hydration and shape effects.
36
3.4. Semi-permeable membrane
500 nm
200 nm
2 µm
500 nm
a b
c d
Figure 3.7: SEM pictures of a nanoporous alumina membrane with a bi-
layer structure: (a) cross section; (b) support layer with 200 nm pores; (c)
zoom over the active layer cross section; (d) active layer with 2–4 nm pores.
cose and ConA dimer is only a factor 9 and thus we have to face the case
where the molecule size and pore size are comparable. A semi-permeable
membrane with a narrow pore size distribution (1–5 nm) is therefore re-
quired.
3.4.2 Nanoporous alumina membrane
Nanoporous anodic alumina membranes were selected as selective inter-
face for the glucose sensor (Fig. 3.7). These membranes exhibit arrays of
straight parallel pores of quasi-uniform shape and have the chemical prop-
erties of a ceramic. They are formed by an electrochemical process involv-
ing the oxidation of high purity aluminium sheets. For small pore sizes,
anodic alumina membranes are generally prepared with a bilayer struc-
ture. These asymmetrical membranes have a thin active layer and a support
layer with larger pores. Typically, the active layer is 0.5 µm thick with 10 nm
pores and the support layer is 50 µm thick with 200 nm pores. This double
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layer configuration ensures rigid membranes whilst allowing good diffu-
sivity properties. The pore diameter is controlled with great precision and
reproducibility, allowing narrow pore size distribution, which is hardly
achieved by other type of membranes. Moreover, annealed anodic alumina
membranes have excellent chemical resistance and long-term stability in
aqueous solution. The smallest pore size commercially available is 2–4 nm
from Synkera Technologies Inc., and they are currently moving towards
manufacturing of nanofitration membranes with 0.5–1 nm pores. With the
right selectivity (pore size and distribution), high permeance, long-term
stability in aqueous solution and intrinsic biocompatibility, anodic alumina
membranes seem therefore well-suited to act as size-selective interface on
the glucose sensor.
3.5 Sensor modeling
3.5.1 Viscosity sensing principle
Modelling aspects of the device are quite important to optimize the sen-
sor with respect to the expected variation of the sensitive fluid viscosity. A
sketch of the sensor principle used for the derivation of the generic analyt-
ical solution is explained in Fig. 3.8.
Under quasi static conditions, the laminar viscous flow of a liquid thr-
ough a circular channel with a length much greater than its diameter, is
described by the Hagen-Poiseuille equation
Q =
piD4
128ηL
∆P (3.1)
where Q is the volumetric flow rate, D and L are respectively the channel
diameter and length, η is the liquid viscosity and ∆P represents the pres-
sure drop across the channel.
On the other hand, the deflection of the center of a piezoelectric di-
aphragm depends on the applied voltage and pressure load. Assuming
small deflections, the relationship is linear and given by
x = αV − βP (3.2)
where x is the deflection of the piezoelectric diaphragm center, V the volt-
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Figure 3.8: Schematic representation of the viscosity sensing principle with
the used notations for the theoretical calculations.
age applied to the piezoelectric diaphragm and P the pressure acting a-
gainst the diaphragm deflection. The coefficients α and β depend on the
diaphragm geometry and material properties. For static deflections of a
circular multi-layered piezoelectric diaphragm, their values are obtained
from the model of Deshpande et al. [80]. As no external voltage is applied
to the sensing piezoelectric diaphragm, its deflection only depends on the
pressure load:
x2 = β2P2 (3.3)
Next, the total volume displaced by a fixed-edge circular diaphragm
under uniform load is given by
V =
1
3
xpiR2 (3.4)
where x and R are respectively the deflection of the center and the radius of
the diaphragm, (note that this equation was derived for a diaphragm under
uniform pressure load and not for a multi-layered piezoelectric diaphragm,
but we will nevertheless use it as a good approximation).
The volumetric flow rate through the channel is equal to the volume
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change under the sensing piezoelectric diaphragm:
Q =
dV
dt
=
piR22
3
dx
dt
(3.5)
Coupling the Hagen-Poiseuille flow through the channel with the piezo-
electric diaphragms deflections, and considering a sinusoidal voltage V1 =
V01 sin(ωt) for actuation, we get the time dependent differential equation:
128ηLR22β1
3D4
dx2
dt
+
(
R22β2 + R
2
1β1
R21β2
)
x2 = α1V01 sin(ωt) (3.6)
The solution of the differential equation is composed of a transient and
a stationary part. Here, we are mainly interested in the stationary solution
describing the deflection of the sensing piezoelectric diaphragm, which is
given by:
x2(t) = Asin(ωt− φ) (3.7)
with
A =
R21β2
R22β2 + R
2
1β1
α1V01√
τ2ω2 + 1
(3.8)
and
φ = arctan(τω) (3.9)
where τ is the relaxation time of the system. The relaxation time is propor-
tional to the liquid viscosity with a constant coefficient depending only on
the geometric and piezoelectric characteristics:
τ = kη (3.10)
with
k =
128L
3D4
R22R
2
1β2β1
R22β2 + R
2
1β1
(3.11)
This means that when a sinusoidal voltage is applied to the actuating
piezoelectric diaphragm, the sensing diaphragm will also deflect harmoni-
cally, but its amplitude and phase shift will now depend on the relaxation
time of the system which is proportional to the liquid viscosity. Next, these
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Figure 3.9: Cross-sectional schematic view of a typical piezoelectric di-
aphragm. The electric field (E) is applied vertically to the plane.
mechanical signals will generate electrical waveforms that will be used to
extract the viscosity of the sensitive fluid.
Aside this analysis, since a time dependent sinusoidal voltage is ap-
plied to the actuating diaphragm, we can wonder if the flow can still be
considered in steady state. When a high viscous liquid pulsates slowly in a
narrow pipe, the instantaneous velocity distribution is given by a parabola
as in the case of steady Poiseuille flow. Uchida demonstrated that the
steady state criteria was still justified provided
√
ω/ν D  1, where ω
is the pulsation of the flow, ν the kinematic viscosity and D the diameter
of the channel [81]. As the sensitive liquid viscosity is several times that of
water and since the channel is only some micrometers in diameter, using
ω = 10 rad/s, ν = 70 mm2/s and D = 100 × 10−6 m, we find a typ-
ical value for the steady state criteria equal to 4.24× 10−2. Therefore, the
quasisteady condition is satisfied and the Hagen-Poiseuille equation can be
used.
3.5.2 Piezoelectric diaphragm deflection
For the sensing principle to operate properly, the deflection of the actuating
diaphragm has to generate a sufficiently large flow for accurately detecting
the viscosity. In addition, the deflection of the sensing diaphragm has to
produce an amount of charges allowing the signal amplification. The ac-
tuating and sensing diaphragms are therefore key elements for the sensor
design.
Basically, a piezoelectric diaphragm consists of a piezoelectric layer cov-
ering partially a passive layer (Fig. 3.9). With parallel electrodes below and
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on top of the piezoelectric layer, the electric field is applied vertically to the
plane and the transverse piezoelectric effect generates in plane strain. This
strain in the piezoelectric layer induces an unimorph effect which produces
a transverse deflection of the diaphragm.
A model describing the static deflections of a circular multi-layered
piezoelectric diaphragm under voltage and pressure loads was developed
by Deshpande et al. [80]. This model relies on the geometry and material
properties of each layers, and applied when the piezoelectric layer covers
the substrate layer only partially. In addition, the model was derived using
the classical laminated plate theory, which implies in particular that small
deflections are considered. The piezoelectric material was also assumed to
be a polycrystalline film polarized along the axis normal to the surface. The
model was validated both numerically via finite element analysis and ex-
perimentally via static deflections of a commercially available piezoelectric
diaphragm. A good agreement was reported between the model, the finite
element results and the experimental measurements.
This analytical model leads to a linear dependence of the piezoelectric
diaphragm deflection upon voltage and pressure loads, which is given by
x(r) = α(r)V − β(r)P (3.12)
where x(r) is the deflection of the piezoelectric diaphragm depending on
the radial position r, and V and P are respectively the voltage and pres-
sure loads. The coefficients α(r) and β(r) depend on the piezoelectric di-
aphragm geometry and material properties in a complex manner. Their
detailed expressions can be found in the article by Desphande et al. [80].
Note that the volume displaced by the diaphragm also depends linearly on
the voltage and pressure loads.
The model was implemented in Mathematica and the deflection of a
typical piezoelectric diaphragm under multiple voltage and pressure loads
was investigated. The diaphragm was made of a 3 mm in diameter, 50 µm
thick layer of lead zirconate titanate (PZT) onto a 3.5 mm in diameter, 10
µm thick brass layer. When applying a voltage to the diaphragm, a dome-
like deflection is produced with the maximal deformation occuring in the
center (Fig. 3.10). A voltage of 30 V generates a deflection of 2.7 µm of
the diaphragm centre, which represents a displaced volume of 12 nl. This
generates a flow over 1.2 mm in a typical 100× 100 µm2 section channel,
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Figure 3.10: Deflections along a diameter of the piezoelectric diaphragm
under a voltage of 30 V and multiple pressure loads.
which should enable precise viscosity sensing.
Generally, the piezoelectric layer covers the substrate layer only par-
tially, which reduces the thickness at the edge and thus favours the dia-
phragm deflection. More precisely, the deflection depends upon the piezo-
electric layer size which can be optimized to maximize the diaphragm de-
flection (Fig. 3.11). In this particular case, as the piezoelectric layer is largely
thicker than the passive layer, a small reduction of the piezoelectric layer
is sufficient to favour the diaphragm deflection. However, when the thick-
ness of the piezoelectric and passive layer are closer, the optimal piezo-
electric radius decreases. According to the model, the optimal ratio of the
piezoelectric and passive layer radiuses mostly depends upon their respec-
tive thicknesses. It does not depend on the voltage or membrane size, and
only slightly on the applied pressure. Note that an optimal piezoelectric
layer size is of primary importance when strong forces are required given
that in this case the deflection is strongly reduced when decreasing the
piezoelectric layer size.
The piezoelectric and passive layers thicknesses also strongly influence
the diaphragm deflection. Depending on the application, thin layers are
used to produce large deflections whereas thicker structures are usefull to
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Figure 3.11: Deflection dependence upon the piezoelectric layer radius for
a constant voltage (30 V) and multiple pressure loads.
generate strong forces. Under constant electric field, the diaphragm deflec-
tion depends on both the piezoelectric and passive layers thicknesses with
optimal values maximizing the deflection (Fig. 3.12). Under pressure load,
both the optimal piezoelectric and passive layers thicknesses increase: the
thicker passive layer stiffens the structure while the thicker piezoelectric
layer is required to generate stronger forces.
3.5.3 Fundamentals of diffusion
Diffusion describes the spread of particles through random motion from
regions of higher concentration to regions of lower concentration. Diffusion
is phenomenologically described by Fick’s law, which relates the diffusive
flux to the concentration by postulating that the flux goes from regions of
high concentration to regions of low concentration, with a magnitude that
is proportional to the concentration gradient. In one dimension, this is
J = −D ∂c
∂x
(3.13)
where J is the flux (amount of particles per unit area per unit time), D is the
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Figure 3.12: Deflection dependence upon the layers thickness for multiple
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(b) passive layer (constant voltage of 30 V).
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diffusion coefficient, c is the concentration, and x is the position.
Combining Fick’s law with the continuity equation which states that a chan-
ge in density in any part of the system is due to inflow and outflow of ma-
terial, we get the diffusion equation predicting how diffusion causes the
concentration to change with time:
∂c
∂t
= D
∂2c
∂x2
(3.14)
Eintein’s theory of Browian motion relates the diffusion coefficient to
the particle mobility as
D = µkBT (3.15)
where µ is the particle mobility, kB is the Boltzmann’s constant, and T is
the temperature. The frictional coefficient (inverse of mobility) exerted on
spherical particles with small Reynolds numbers (Re1) in a viscous fluid
is given by
γ = 6piηr (3.16)
where η is the dynamic viscosity and r is the radius of the spherical particle.
Combining (3.15) and (3.16), we get the Einstein-Stokes equation which ex-
presses the diffusion coefficient of spherical particles through liquids with
low Reynolds numbers:
D =
kBT
6piηr
(3.17)
3.5.4 Diffusion in membranes
A simple way of describing diffusion through membranes is to consider
two well-stirred volumes separated by a membrane (Fig. 3.13). In partic-
ular, this diffusion cells configuration is used to characterize the diffusion
properties of membranes. To achieve this, a chamber is filled with a solu-
tion of known concentration and the other chamber is filled with solvent.
Next, the concentration is measured at regular intervals and the diffusion
coefficient is extracted from the concentration dynamics. An exact solu-
tion to this problem is elaborate and unnecessary for practical use [82].
The useful approximate solution depends on the assumption that the flux
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Figure 3.13: Diffusion through a porous membrane separating two well-
stirred solutions. Vi and Ci are respectively the volume and concentration
of the chamber i, and c(x) is the concentration inside the membrane.
across the membrane quickly reaches its steady-state value [83], and that a
steady-state flux is approached even though the concentrations in the two
chambers are changing with time.
In the case of steady diffusion, each side of the membrane is a well-
mixed dilute solution of fixed concentration. In these conditions, the con-
centration in the membrane does not change with time and the diffusion
equation (3.14) becomes
d2c
dx2
= 0 (3.18)
where c is the concentration in the membrane depending on the position x.
The boundary conditions relating the concentration in the membrane to
the fixed concentrations C1 and C2 of the dilute solutions are given by
c = HC1 for x = 0 (3.19)
c = HC2 for x = l
where H is the partition coefficient, which is the concentration in the mem-
brane divided by that in the adjacent solution. The partition coefficient is
an equilibrium property, which takes into account the relative solubility in
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the membrane compared with that in the adjacent solutions. For porous
membranes, it also includes the porosity which is the pores-to-membrane
area ratio.
The concentration profile in the membrane is obtained by integrating
the diffusion equation (3.18) using the boundary conditions (3.19):
c = HC1 + H (C2 − C1) xl (3.20)
The solution is a linear change of concentration across the membrane which
depends upon the membrane properties through the partition coefficient.
The flux across the membrane is found by combining the concentration in
the membrane (3.20) with Fick’s law (3.13):
J = −HD
l
(C2 − C1) (3.21)
We next write an overall mass balance on the adjacent chambers, expressed
by
V1
dC1
dt
= −SJ (3.22)
V2
dC2
dt
= +SJ (3.23)
where S is the membrane area. Coupling these mass balance equations
with the flux equation (3.21), we obtain the differential equation for the
concentration of the dilute solutions:
d
dt
(C2 − C1) = −HDSl
V1 + V2
V1V2
(C2 − C1) (3.24)
The solution of this differential equation is given by
(C2 − C1) = (C2,0 − C1,0) exp
(
− t
τ
)
(3.25)
with
τ =
l
HDS
V1V2
V1 + V2
(3.26)
This means that the concentration of two well-stirred solutions sepa-
rated by a porous membrane evolves towards the equilibrium following an
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exponential relation. The time constant of this diffusion process depends
upon the diffusion coefficient, the membrane geometry and diffusive prop-
erties, and the size of both chambers. When considering two chambers with
identical volumes and an effective diffusion coefficient, the time constant
becomes
τ =
lV
2DeffS
(3.27)
For nanoporous membranes, an effective diffusion coefficient is often
considered, as many effects may restrict diffusion. In particular, the dif-
fusion rate may be greatly slowed if the dimensions of the pores are com-
parable with those of the diffusing molecules. In fact, it was shown that
the rates of diffusion of organic non-electrolytes through membranes with
very small pores decrease, as a function of molecular size, far more rapidly
than can be accounted for on the basis of the free diffusion coefficients of
the test molecules [84]. It also appears that diffusion is severely restricted
even when the pores are of the order of 20 times larger than the diffusing
molecules [85]. The increased viscous drag in the pore and the particle-pore
wall interaction could explain this diffusion reduction. A further restriction
to diffusion may result from steric effects at the entrance to the pore, as the
diffusing molecules can enter a pore only if they do not strike the edges
[86].
With a factor 9 between glucose and ConA hydrodynamic radiuses, our
sensor is characterized by a high solute-to-pore ratio, which means that the
glucose diffusion through the nanoporous membrane will likely be reduced
compared to diffusion in solution.
3.5.5 Free diffusion
For the glucose concentration to be in equilibrium with the surrounding en-
vironment, glucose molecules have first to diffuse across the nanoporous
membrane, and then in the sensitive fluid. This is a free diffusion which
can be approximately described by the diffusion in a semi-infinite slab
(Fig. 3.14). The slab initially contains a uniform concentration of solute. At
time t = 0, the concentration at the interface is suddenly increased, which
is described by the following boundary conditions:
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Figure 3.14: Free diffusion in a semi-infinite slab. The concentration at
the left is suddenly increased to a higher constant value, which induces
diffusion in the region to the right. (Reprinted from [87].)
c(x) = C∞ for all x at t = 0 (3.28)
c(x = 0) = C0 at t > 0
c(x = ∞) = C∞ at t > 0
The concentration at x = ∞ is constant because it is so far from the inter-
face as to be unaffected by events while the concentration at x = 0 is kept
constant by adding material at the interface.
The solution is found by solving the diffusion equation (3.14) with the
boundary conditions (3.28) using the definition of the variable ξ = x/
√
4Dt,
(the detailed resolution of this problem can be found in [87]):
c(x, t)− C0
C∞ − C0 = erf
(
x√
4Dt
)
(3.29)
where
erf(ξ) =
2
pi
∫ ξ
0
exp
(−s2)ds (3.30)
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is the error function.
The expression ξ = x/
√
4Dt completely determines the concentration
at the position x and time t, which means that the same diffusion level
is achieved for ξ constant. The length
√
4Dt, called the diffusion length,
provides a measure of how far the concentration has propagated at time t.
It is worth noticing that the diffusion time depends quadratically upon the
distance and linearly upon the diffusion coefficient. This implies that the
sensor has to be as small as possible to minimize the diffusion length and
thus reduce the response time. A good diffusion coefficient is also useful
to favour the diffusion process. According to the Eintein-Stokes relation
(3.17), the diffusion constant decreases with the fluid viscosity due to an
increased viscous drag slowing the particle movement. A low-viscosity
sensitive fluid is therefore also required for rapid measurement.
3.6 Conclusion
In this chapter, we described and modeled the sensing principle relying on
the viscosity variation of a ConA-based sensitive fluid. With a hydrody-
namic radius of 3.3 nm, the confinement of ConA require a nanofiltration
membrane with a narrow pores size distribution. Nanoporous alumina
membranes were selected as they are characterized by a rigid structure, a
narrow pores size distribution, and a long term stability in aqueous solu-
tion. Concerning the sensor modeling, we showed that when applying a
sinusoidal voltage the system oscillates harmonically with amplitude and
phase shift which depend on the sensitive fluid viscosity. The use of piezo-
electric diaphragms was also validated by simulation, showing that small
diaphragms can produce significant deflections. Finally, we expose a sim-
ple exponential model for glucose diffusion in membranes, which allows
to experimentally determine the diffusion constant using diffusion cells.
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4.1 Introduction
The sensor topology was designed to allow its realization in microelec-
tromechanical system (MEMS) technology. Its flat and stack-based struc-
ture is in fact especially well-suited for microfabrication batch processes
like etching, thin film deposition, and patterning. The two chambers and
the microchannel could be etched in silicon using existing microfabrica-
tion processes (Fig. 4.1). Such structures are commonly fabricated in sili-
con for lab-on-a-chip applications. Piezoelectric thin films and their inte-
gration in MEMS technology have also been subject to intensive research,
and a number of devices based on PZT (lead zirconate titanate) thin films
were successfully fabricated [88]. However, piezoelectric thin film fabrica-
tion is still a complex technology which is mastered by a limited number
of research groups. Moreover, MEMS technology often brings miniatur-
ization issues, especially for microfluidic devices. For these reasons, we
chose to demonstrate the sensing principle using macroscopic technologies.
The sensor was realized in stereolithography, also known as 3D printing,
which allows to create plastic objects using laser-induced polymerization
of a photo-curable resin. The object is created by successively printing thin
layers of ultraviolet curable material on top of each other. Stereolithogra-
phy allows rapidly creating prototypes with high accuracy.
In this chapter, the development and assessment of the sensor in iso-
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1.5 mm
4 mm
Microchannel
Length 0.8 mm
Section 50 × 50 µm2
Cavity
Diameter 1 mm
Depth 295 µm
Filling channel
Width 100 µm 
Depth 50 µm
0.3 mm
Figure 4.1: Schematic view of the MEMS sensor concept with optimal di-
mensions.
tonic saline solution are presented.
4.2 Sensor design
4.2.1 Sensor structure
According to the sensor model, a microchannel of about 50–100 µm was re-
quired to detect viscosity with a small size sensor. Such a microchannel is
not feasible by standard stereolithography; with layers thickness of 50 µm,
the smallest achievable channel is 300 µm. A glass capillary was therefore
integrated in the stereolithography housing (Fig. 4.2). In addition, the actu-
ating and sensing chambers were both defined by circular apertures in the
stereolithography housing and sealed by circular piezoelectric diaphragms
and nanoporous membranes. Two filling channels were also included on
both sides of the stereolithography housing. Finally, the thickness of the
chambers was minimized in order to keep a small diffusion length and
hence a good response time.
4.2.2 Actuating piezoelectric diaphragm
For accurately detecting viscosity, the actuating diaphragm has to generate
a large flow through the microchannel with sufficient pressure. A flow
54
4.2. Sensor design
Actuating diaphragm Sensing diaphragm
Nanoporous membrane
Glass capillary
Filling channel
Figure 4.2: Schematic section view of the sensor design including a glass
capillary as microchannel.
through the whole microchannel is also required to equilibrate the glu-
cose concentration inside the microchannel. Piezoelectric ceramics gener-
ate strong forces and large excursions in bending structures and are there-
fore well suited for the actuating diaphragm. In particular, PZT is a ce-
ramic perovskite material which exhibits outstanding piezoelectric proper-
ties. These properties make PZT-based compounds one of the mostly used
piezoelectric ceramics. Important fields of application are actuators for mi-
cropositioning, sensors such as conventional vibration pickups, and ultra-
sonic transmitters and receivers, like automotive parking radars. Among
these, piezoelectric diaphragm is a basic electronic sound component char-
acterized by a simple structure, stable performance and high reliability. It
is used for buzzers and alarms, as well as shock sensors in many sensitive
equipments.
The smallest piezoelectric diaphragm commercially available is a 5 mm
diameter, 50 µm thick PZT layer onto a 6.5 mm diameter, 50 µm thick
brass layer (Audiowell electronics, Ltd.). As a quite small sensor was tar-
geted, the handmade fabrication of smaller piezoelectric diaphragms was
required. When decreasing the size of a piezoelectric diaphragm, its thick-
ness must be reduced accordingly to maintain good bending properties.
However, the minimum thickness of commercially available PZT layers is
50 µm, which limits the miniaturization of the diaphragm. The brass layer
thickness was reduced to 10 µm, which allowed to decrease the diaphragm
size to 3.5 mm (Fig. 4.3). The diaphragm deflection was characterized us-
ing a specular-reflective laser displacement meter (LC-2420 from Keyence)
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3.5 mm
3 mm
50 µm
PZT layer Brass layer
10 µm
3.5 mm
3 mm
28 µm
PVDF layer Brass layer
10 µm
a b
Figure 4.3: Dimensions of the actuating (a) and sensing (b) piezoelectric
diaphragms.
(Fig. 4.4). The piezoelectric diaphragm model describes accurately the di-
aphragm deflection for small voltages. However, large deflections are un-
derestimated by the model with a quite important deviation from the ex-
pected linear behaviour. This could be explained by an increase in polariza-
tion with the magnetic field, which would increase the piezoelectric effect.
The model relies on a constant piezoelectric coefficient, and therefore this
non-linear behaviour is not taken into account. However, the theoretical
and experimental values are of the same order of magnitude, which allows
to properly estimate the sensor response.
In operation, a voltage of 30 V was applied to the diaphragm, which
generates a deflection of 2.7 µm of the diaphragm center and corresponds to
a flow of 1.2 mm in the 100× 100 µm2 section channel. Such a high voltage
was imposed by the sensor design, as a flow through the whole capillary
is required to mix the sensitive fluid inside the microchannel. Since a high
voltage is not compatible for in vivo applications, we can wonder whether a
lower actuating voltage could also be used. The voltage could be reduced
by decreasing the microchannel dimensions, as the flow required to mix
the sensitive fluid would be reduced. For instance, a voltage of 5 V could
be used with a 500 µm length, 50×50 µm2 section microchannel. The volt-
age could also be reduced by decreasing the piezoelectric layer thickness,
as an equivalent electric field would be produced with a lower voltage.
However, as commercially available piezoelectric diaphragms have a mini-
mum thickness of 50 µm, a dedicated fabrication would be required. In the
case of MEMS fabrication, PZT thin-film diaphragms could be directly inte-
grated in the device [89]. Finally, the need to produce a flow across the mi-
crochannel could be suppressed if glucose could directly diffuse into a mi-
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Figure 4.4: Deflection of the actuating piezoelectric diaphragm under volt-
age load.
crochannel with a porous side wall. For instance, the alumina nanoporous
membrane could be used to seal an open microchannel. This would be the
ideal case since the only remaining constraint on the deflection would be
the detection of the sensing signal. Therefore, solutions exists to decrease
the actuating voltage, but this was not the primary focus for this proof of
concept sensor.
4.2.3 Sensing piezoelectric diaphragm
For the sensing principle to work properly, the sensing diaphragm has to
bend more easily than the nanoporous membrane, otherwise the nano-
porous membrane would deform instead of the sensing diaphragm and
the flow would not be detected. According to the piezoelectric diaphragm
model, the PZT diaphragm used as actuator is 1.7 times stiffer than the
50 µm thick alumina nanoporous membrane, implying that a more flexi-
ble structure has to be used for the sensing side. Polyvinylidene fluoride
(PVDF) is a thermoplastic fluoropolymer which exhibits a large piezoelec-
tric coefficient as well as a low elastic modulus. The piezoelectric properties
of PVDF are used to manufacture tactile sensor arrays, inexpensive strain
gauges and lightweight audio transducers. A 28 µm thick PVDF foil was
57
Chapter 4. Sensor development and assessment
0 0.02 0.04 0.06 0.08 0.1
0
10
20
30
40
50
60
Viscosity @PasD
P
h a
s e
s h
i f t
@ d
e g
D
i ity [mPas]
P
h a
s e
 s
h i
f t  
[ d
e g
]
10 Hz
6 Hz
3 Hz
1 Hz
20 40 60 80 100
Figure 4.5: Theoretical phase shift of the sensor calculated using the sensor
model (Eq. (3.9)).
therefore used as piezoelectric layer on the sensing diaphragm (Fig. 4.3).
For practical reasons, a 10 µm thick brass foil was also used as passive layer
and the size of the actuating and sensing diaphragms was the same. Ac-
cording to the piezoelectric diaphragm model, this brass-PVDF diaphragm
is 16 times more flexible than the alumina nanoporous membrane, which
makes it a well suited sensing diaphragm.
4.2.4 Measurement process
The actuating frequency may be tailored according to the sensitive fluid
viscosity. The same phase shift is indeed maintained by increasing the ac-
tuating frequency when using a lower viscosity sensitive fluid. The higher
measurable viscosity is defined by the lower possible frequency, which is
limited by the instrumentation amplifier used to measure the piezoelectric
signal. A minimum frequency of 1 Hz is required by most amplifiers. On
the other hand, when using a lower viscosity, the frequency can always
be increased and consequently no lower viscosity limit exists. However,
a small channel with a high fluidic resistance provides a better measure-
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Glass capillary 
location
Actuating diaphragm 
location
Aperture for the 
actuating chamber
Actuating and sensing 
chambers
Locations for the coaxial 
electric connectors
Filling channel
10 mm
5.5 mm
Figure 4.6: Picture of the sensor housing fabricated by stereolithography.
ment accuracy; it is therefore better to operate at low frequency. A vis-
cosity measurement range has therefore to be defined, while the actuating
frequency is used to tailor the phase shift. Our sensor was designed to
measure low viscosity sensitive fluids (10–100 mPas) at low frequency (1–
10 Hz) (Fig. 4.5).
4.3 Experimental section
4.3.1 Sensor fabrication
The piezoelectric diaphragms were prepared by cutting 4 mm diameter
discs from a 10 µm thick brass foil (Goodfellow) using laser ablation (LS-
520G Nd:YAG 1064 nm from Laser Systems). A 3 mm diameter PZT disc
was also cut by laser ablation from a 50 µm thick PZT layer provided by Au-
diowell Electronics. Next, a 3 mm diameter disc was punched in a 28 µm
thick PVDF foil provided by Measurements Specialties. The piezoelectric
diaphragms assembly was performed by gluing the PZT and PVDF discs
onto brass discs using a low-viscosity epoxy adhesive (Loctite M-31CL). In
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Sensing piezoelectric 
diaphragm
Actuating piezoelectric 
diaphragm
Nanoporous alumina 
membrane
a b
Figure 4.7: Pictures of the assembled sensor showing the actuating and
sensing piezoelectric diaphragms (a) and the nanoporous alumina mem-
branes (b).
addition, electric contacts were achieved by bonding 0.1 mm copper wires
using a conductive adhesive epoxy (EPO-TEK E4110 from Epoxy Technol-
ogy). Finally, the piezoelectric diaphragms were coated with 10 µm pary-
lene C to prevent any corrosion caused by water contact. Such coating was
chosen because parylene is a chemically very stable polymer deposited at
room temperature.
The sensor housing was manufactured by stereolithography using a
biocompatible medical-grade resin (Proform, Part. DSM XC11122) (Fig. 4.6).
The housing included two 3.5 mm diameter circular apertures for the ac-
tuating and sensing chambers, two 0.3 mm diameter filling holes, as well
as dedicated locations for the glass capillary, the piezoelectric diaphragms
and the alumina membranes. The semi-permeable membrane was a 50 µm
thick alumina nanoporous membrane with 2–4 nm diameter pores (Synkera
Technologies, Inc.). In addition, a 1 mm length, 100×100 µm2 section glass
capillary was used for the microchannel (Vitrocom, Part. ST8510). The sen-
sor assembly was realized using medical-grade adhesive epoxy (Loctite M-
21HP) using a precision syringe dispenser and a stereoscopic microscope
(Fig. 4.7). Finally, the sensor was 200 µm thick, which was imposed by the
outer dimension of the glass capillary, and contained 4 µl of sensitive fluid.
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4.3.2 Sensitive fluid characteristics
The sensitive fluid consists in 2% [w/w] dextran 3200 (PSS) and 0.4% [w/w]
ConA (Sigma) in a buffered saline solution (10mM Tris base, 1mM CaCl2,
1mM MnCl2, 0.05% NaN3, 0.15M NaCl). Two metal ions, Mn2+ and Ca2+,
were added to the solution to activate the glucose binding site of ConA.
This conformational change strongly increases its affinity to glucose. The
pH was adjusted to the physiological value (pH 7.4), which also ensures a
maximal proportion of tetrameric ConA able to bind up to 4 glucose groups
and form a large network. The saline concentration was set to its physio-
logical value (0.15M NaCl) and NaN3 was added as preservative. The vis-
cosity of the sensitive fluid was characterised using a capillary viscometer.
Its values were ranging from 5.9 to 16.7 mPas at 25˚C and from 4.2 to 9.4
mPas at 37˚C (Fig. 3.3).
4.3.3 Sensitive fluid preparation
To prepare the sensitive fluid, 3 stock solutions were necessary.
Stock solution 1 was prepared by dissolving 20 mM of Trizma buffer
pH 7.4 (Sigma, Cat. T-7693), 0.1% [w/w] of sodium azide (Riedel-de Haen,
Cat. 13412) and 4 mM D-(+)-glucose anhydrous (Fluka, Cat. 49138) in mil-
lipore water.
Stock solution 2 contained 2 mM calcium chloride dehydrate (Fluka,
Cat. 21101), 2 mM manganese II chloride tetrahydrate (Riedel-de Haen,
Cat. 31422) and 300 mM sodium chloride (Fluka, Cat. 71379).
Stock solution 3 was a 50 mM sodium hydroxide (Fluka, Cat. 71691)
aqueous solution, which was used for the pH adjustment of the sensitive
fluid.
The sensitive fluid was prepared by dissolving dextran (Polymer Stan-
dards Service, Cat. dxtb3m) in stock solution 1 and ConA (Sigma, Cat.
C2010) in stock solution 2, as described below.
Solution A: Twice the concentration of the final preparation of dextran
was dissolved in stock solution 1 and mixed at room temperature for at
least 10 h.
Solution B: Twice the concentration of the final preparation of ConA
was dissolved in stock solution 2. The pH was adjusted to 7.4 by carefully
adding stock solution 3. Since this step is very critical, care was taken to
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Figure 4.8: Experimental in vitro setup.
add the sodium hydroxide at a slow and controlled flow rate with constant
mixing. If the transition is made too fast ConA tends to be denaturated and
precipitates. However this process should not take too long either, because
ConA has a tendency to precipitate in the absence of dextran. The solution
was centrifuged at 4600 turns/min for 10 min.
One volume of solution A was put in a new recipient and the same
volume of solution B (filtered through a Millex HV 0.45 µm syringe filter)
was added. The obtained preparation was thoroughly mixed by shaking.
4.3.4 Experimental setup
As the viscosity of the sensitive fluid is temperature-dependent, the whole
setup was located in a thermally regulated enclosure (±0.01˚C) (Fig. 4.8).
The temperature of the thermostatic chamber was monitored with a high
precision thermometer (GMH 3710 from Greisinger GmbH) and was reg-
ulated using a Peltier element controlled by a PID (proportional-integral-
derivative) algorithm implemented in LabVIEW.
The sinusoidal voltage generation and acquisition were performed us-
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ing a multifunction data acquisition board (PCI-6052E from National In-
strument). The actuating piezoelectric diaphragm was driven with a low-
frequency sinusoidal voltage (1-5 Hz) amplified up to 30 V by means of a
high voltage amplifier (WMA-02 from Falco Systems). The sensing voltage
was amplified using an instrumentation amplifier (AD8661 from Analog
Device). The voltage generation, acquisition and phase shift computation
were performed using a LabVIEW interface. The phase shift was deter-
mined by fitting the sensing signal with a sinusoidal function using the
least square regression method.
To evaluate the characteristics and response of the device, glucose mea-
surements were performed in an isotonic saline solution which had the
same composition as the sensitive fluid except dextran and ConA. This
solution was characterized by physiological values of the pH and saline
concentration. The two metal ions used to activate the glucose binding site
of ConA, Mn2+ and Ca2+, were added to the solution to ensure a good
stability of the sensitive fluid. Sodium azide (NaN3) was used as preserva-
tive, and concentrated (2M) D-glucose was added to increase the glucose
concentration to the desired level.
The sensor was enclosed in a dedicated housing containing the solution
to be measured. Glucose solutions of varying concentrations were pumped
into the test cell using a computer controlled syringe pump (Tecan Cavro
XCalibur). A 9-port ceramic valve was used for the evaluation of multiple
test solutions.
4.4 Results and discussion
4.4.1 Demonstrating the viscosity sensing principle
Before implementing the glucose sensor, the viscosity sensing principle
was first demonstrated using a system consisting of two piezoelectric di-
aphragms and a microchannel, which was filled with viscosity reference
standards (Paragon Scientific, Ltd.). Phase shift measurements were per-
formed with five different reference standards exhibiting dynamic viscosi-
ties ranging from 3.65–17.25 mPas (Fig. 4.9). As expected from the model,
the tangent of the phase shift depends linearly upon the viscosity. The
mean standard deviation was about 0.2%, which shows the potential ac-
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Figure 4.9: Phase shift measurements of different viscosity reference stan-
dards at 20˚C.
curacy of this detection method. Moreover, the deviation from the linear
curve may be due to the need to open and change the viscosity reference
standard, which may lead to systematic errors from one measurement to
the other. This will not be the case for the glucose sensor, and we could
therefore expect a much better reproducibility.
4.4.2 Sensor characterization at various temperatures
The sensor was characterized at 25 and 37˚C. Stepwise increasing levels
of glucose concentrations (2-4-7-11-16 mM) have been used, followed by
similar decreasing glucose concentrations (16-11-7-4-2 mM) (Fig. 4.10). The
data indicates that the sensing principle is highly reversible; the phase shift
characterizing a glucose level is the same after increasing or decreasing the
glucose concentration.
The reversibility of the sensitive solution was expected since the re-
versibility of the ConA-saccharide binding was previously demonstrated.
Nevertheless, the difficulty is the confinement of the sensitive fluid in-
side the sensor, provided that ConA is a small protein. The ConA hy-
drodynamic radius in tetramer configuration (highly prevailing at pH 7.4)
is 4.4 nm whereas the nanoporous alumina membrane pores distribution
was 2–4 nm. The high degree of reversibility obtained implies that ConA
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Figure 4.10: Phase shift response to stepwise increasing and decreasing
glucose concentrations (2, 4, 7, 11, 16 mM) in isotonic saline solution at 25
and 37˚C.
molecules in tetramer configuration were well confined by the alumina
membrane. Moreover, a good reversibility was also obtained at high glu-
cose concentration, which emphasizes the good retention capabilities of the
alumina membrane. ConA leakage should indeed be favoured at high glu-
cose concentration, when the network ConA-dextran is untied and as a
result, ConA is free to diffuse through the nanoporous membrane. More-
over, the response time of the sensor did not increase with time, indicat-
ing that dextran and ConA did not clog the pores. The sensing principle
worked well, glucose diffusing freely in and out of the sensor through the
nanoporous membrane, whereas the sensitive fluid was completely con-
fined inside the sensor.
For in vivo applications, the sensor has to properly operate at physiolog-
ical temperature. We therefore evaluated the sensor at 37˚C, to check that
the temperature increase does not impede the sensor function. Potential is-
sues are mostly related to the microfluidic part, as evaporation and air bub-
ble formation are favoured at higher temperature. The sensor functioned
well at 37˚C, which demonstrates the robustness of the sensing principle.
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Figure 4.11: Sensor response to increasing and decreasing glucose concen-
trations fitted with an exponential model.
Finally, we observe that the degree of glucose-induced phase shift change
is reduced by about 55% when the temperature increases. This was ex-
pected, since the sensitive fluid viscosity is highly temperature dependent.
However, the reduced sensitivity at 37˚C does not represent a practical lim-
itation for the detection of the glucose concentration provided that some
calibrations are carried out.
4.4.3 Sensor response dynamics
The sensor kinetics is mostly governed by the glucose diffusion through
the nanoporous membrane and in the sensitive fluid. Both diffusion pro-
cesses are free diffusions, approximately described by the diffusion in a
semi-infinite slab whose solution is given by the error function (see section
3.5.5). The sensitive fluid is also mixed in the vicinity of the glass capillary
by the alternative flow, which speeds up the sensor response compared to
a purely diffusive process.
Experimentally, the diffusion of glucose in-outside of the sensor was
well described by an exponential model (Fig. 4.11). The response time was
determined by fitting the sensor response to glucose variations using an
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exponential relationship given by
y = A(1− e− tτ ) + B (4.1)
where τ is the relaxation time. In sensor technology, the response time
is commonly expressed as τ90%, which is the response time of the sensor
to reach 90% of the variation amplitude. For this exponential relationship
(4.1), the response time is given by τ90% = ln(10)τ.
The response time of the sensor was determined by fitting the sensor
response to multiple glucose concentrations at 25 and 37˚C. The response
time was averaged over 20 measurements for each temperature (Fig. 4.12).
At 37˚C, the response time of the sensor was 3.6± 0.7 min when increas-
ing glucose concentrations, and 12.8± 1.4 min for the decreasing case. The
longer time constant related to decreasing glucose concentrations could be
explained by a smaller mobility of glucose molecules in the viscous sensi-
tive fluid with respect to the isotonic saline solution. This smaller mobility
would increase the time required for glucose molecules to find a pore, con-
sequently slowing down the diffusion process when glucose diffuse out of
the sensor. Therefore, we expect that the porosity of the semi-permeable
membrane affects more the glucose molecules leaving the sensor than glu-
cose molecules entering the sensor.
The sensor kinetics was improved when increasing the temperature
from 25 to 37˚C due to the reduction of the sensitive fluid viscosity. A
stronger reduction of the response time was observed for increasing glu-
cose concentration (51%) than for the decreasing case (16%). As the diffu-
sion time in a solution is directly proportional to its viscosity, the response
time reduction may be compared to the mean viscosity decrease of the sen-
sitive fluid (38%). From these results, it seems that the glucose diffusion
in the sensor directly depends on the sensitive fluid viscosity, whereas the
diffusion out of the sensor is also limited by an other factor. Both diffusion
in and out of the sensor were expected to strongly depend upon the vis-
cosity and this difference is hardly explained. A hypothesis could be that
the glucose diffusion out of the sensor is more importantly restricted by the
membrane porosity.
The response time achieved by our device was slightly longer than our
targeted 10 min response time required for a medical device. This response
time may be shortened by reducing the sensor thickness since this would
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Figure 4.12: Response time of the sensor for increasing and decreasing
glucose concentrations at 25 and 37˚C.
decrease the length for molecules to diffuse, and therefore would decrease
the diffusion time. The relaxation time for diffusion is given by τ ∝ L2,
where L is the characteristic length. According to the above relation, a cav-
ity thickness of 150 µm should achieve a response time less than 10 minutes.
Such a dimension is quite standard in microengineering technologies.
4.4.4 Sensor accuracy and stability
For assessing reproducibility and stability, the sensor was tested in the most
relevant physiologically glucose concentrations, namely 2 mM and 20 mM
(Fig. 4.13). Seventeen full cycles performed without interruption during
70 hours demonstrated a high reversibility and stability of the sensor. The
phase shift difference between 2 and 20 mM was constant throughout the
measurements.
For each equilibrium value of glucose concentration, 400 measurements
were averaged, leading to a mean standard deviation of 0.045 deg. The glu-
cose sensitivity was 2.64 deg/mM, which combined with a 95% confidence
interval of 0.09 deg (2σ), results in an accuracy of 0.034 mM. This value is
comparable to the 1 mg/dl (0.056 mM) resolution of conventional glucose
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Figure 4.13: Phase shift response to seventeen full cycles of glucose con-
centrations (2 mM and 20 mM) in isotonic saline solution at 25˚C.
meters. In addition, when compared to a reference method, most of the
glucose meters have an accuracy characterized by ∼95% of the readings in
a ±20% deviation limit [90]. The sensor accuracy corresponds to a relative
deviation of ±1.7% for a low hypoglycaemic value (2 mM), which con-
firms that the sensor resolution is accurate enough for patients monitoring.
Moreover, no decrease in the sensor sensitivity was observed, demonstrat-
ing a high stability.
4.5 Conclusion
A glucose sensor demonstrator was developed and extensively tested in
isotonic saline solution for physiological blood glucose concentrations be-
tween 2 and 20 mM. The quite high accuracy of ±1.7% in the hypogly-
caemic range demonstrates the ability of this sensor for accurate glucose
monitoring. A good degree of reversibility and stability of the sensor was
also demonstrated for up to 3 days. Concerning its time response, we re-
port a value of 12.8 min at 37˚C, which is only slightly above the 10 min re-
quired for medical applications. These results suggest that the combination
of the ConA-based sensitive fluid and the microviscometer is a promising
sensing principle for continuous glucose monitoring.
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Chapter 5
Long term performance study
of the sensor
5.1 Introduction
The sensor showed an excellent behaviour up to 3 days, which is promising
for short term applications. Beside that, a long term implantable sensor is
also highly desirable for diabetic patients. In this chapter, we therefore
focus on the long term stability of the sensor, which is mandatory for such
application.
The long term stability of the sensor was investigated by continuously
cycling glucose concentrations at body temperature during 25 days. We
also studied in detail the 2–4 nm nanoporous alumina membrane, which
is a key for the long term stability since it has to confine the sensitive fluid
whilst allowing fast glucose permeation. As ConA is a small protein, a
defect-free membrane with a well defined pore size distribution is required
for ensuring a perfect retention.
The size-selective diffusion in nanoporous alumina membranes was in-
vestigated using diffusion cells. ConA retention and glucose diffusion were
measured using respectively ultraviolet absorption spectrometry and re-
fractometry. In addition, the pores size distribution and the porosity were
characterized using scanning electron microscopy. We also evaluated pores
narrowing by atomic layer deposition as a mean to improve the retention
properties of nanoporous alumina membranes.
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Figure 5.1: Glucose diffusion and ConA retention were evaluated using
diffusion cells. The concentration of permeating molecules was monitored
by refractometry or UV absorbance spectrometry during tests.
5.2 Experimental description
5.2.1 Diffusion cells
The ConA retention and glucose diffusion properties of 2–4 nm annealed
nanoporous alumina membranes from Synkera Technologies were assessed
using home-made diffusion cells fabricated in PMMA (poly(methyl metha-
crylate)) (Fig. 5.1). The two diffusion cells had a volume of 140 µl with a
diffusing surface of about 28 mm2. The two chambers were separated by
the nanoporous membrane, which was glued using medical-grade adhe-
sive epoxy (Loctite M-21HP) for ensuring leak-tight measurements. First,
a solution with a given concentration of the solute was injected in the first
cell while pure solvent was injected in the second one. Both cells could be
stirred by standard PTFE (Teflon) magnetic stirrers. The solute diffusion
was monitored by measuring the solute concentration by either refractom-
etry or UV absorbance spectrometry.
5.2.2 Refractometry
The glucose concentration was determined by measuring the refractive in-
dex of the solution using a high precision refractometer (Bellingham and
Stanley RFM 342). A volume as small as 60 µl is required for refractive in-
dex measurements carried out at the reference wavelength of 589.3 nm (the
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sodium D line). The refractive index depends almost linearly on glucose
concentration. An accuracy of ∼ 4× 10−4 is reported, which corresponds
to 1.5 mM of glucose concentration.
For determining the glucose diffusion, the two diffusion cells were re-
spectively filled with a 100 mM glucose solution and ultrapure water. Be-
fore each experiment, a two points calibration curve was performed by
measuring the refractive index of the 100 mM glucose solution and ul-
trapure water. Both chambers were stirred during the whole experiment
and measurements were recorded at regular intervals. A sample was with-
drawn from the diffusion cell and placed on the refractometer crystal for
the measurement, after what the solution was put back in the diffusion
cell. The refractive index values were converted to glucose concentrations
using the calibration curve.
5.2.3 UV absorbance spectrometry
UV absorbance spectrometry was used to quantify the concentration of
ConA in solution. The tyrosine (274 nm) and tryptophan (280 nm) aromatic
amino acids were detected as they are the most absorbing components of
proteins. The UV light was transmitted via an optical fiber from the UV
light source (DT-MINI-2-GS from Ocean Optics), then passed through the
sample contained in a micro-cuvette (70 µl), and was collected by a spec-
trometer (USB4000-UV-VIS from Ocean Optics). The intensity of the trans-
mitted UV light was measured by the spectrometer and a reference was
used to determine the relative absorption induced by ConA. A calibration
spectra was determined using isotonic saline solutions containing various
ConA concentrations in the range of the sensitive fluid (0.01–0.1% [w/w])
(Fig. 5.2). A linear correlation was found between the ConA concentration
and the relative absorbance at 280 nm, which was used to quantify ConA
diffusion.
It is known that ConA is instable in solution and precipitates after a
few hours. As its solubility is strongly increased in presence of dextran
[91], the retention experiments were performed using the sensitive fluid.
The two diffusion cells were respectively filled with the sensitive fluid and
the isotonic saline solution. The glucose concentration of both solutions
was 30 mM, a relatively high concentration where most ConA molecules
are in their unbounded state, which favours their diffusion through the
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Figure 5.2: (a) UV absorbance spectra of various ConA concentrations in
isotonic saline solution. (b) Calibration curve of the absorbance at 280 nm
as a function of ConA concentration.
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Figure 5.3: Long term measurement of glucose concentrations (2 mM and
12 mM) in isotonic saline solution at 37˚C.
nanoporous membrane. For determining the ConA diffusion coefficient,
a sample of isotonic saline solution was removed from the diffusion cell
and placed in the micro-cuvette for recording the UV absorption spectrum.
The ConA retention was evaluated by measuring its concentration in the
isotonic saline solution every 24 hours, after what the solution was replaced
by a fresh one.
5.3 Results and discussion
5.3.1 Long term stability of the sensor
The long term stability of the sensor at 37˚C was investigated by varying
glucose concentrations (2 and 12 mM) every 12 hours for a total of 25 days
(Fig. 5.3). The sensor worked well during the whole experiment, glucose
diffusing freely in and out of the sensor through the nanoporous mem-
brane, whereas the sensitive fluid was still confined inside the sensor. This
good behaviour throughout the experiment also demonstrates the excellent
long term stability of the membrane in aqueous solution at 37˚C. More-
over, the response time of the sensor did not increase with time, indicat-
ing neither dextran nor ConA clogged the pores. Beside these promising
characteristics, the sensor sensitivity decreased linearly with a reduction
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Figure 5.4: Loss of sensitivity of the long term measurement expressed as
percentage of the initial sensitivity.
of 1.3% per day (Fig. 5.4). Multiple effects could account for the sensitiv-
ity reduction, as an incomplete confinement of the sensitive fluid, ConA
deactivation, or mechanical fatigue of the piezoelectric diaphragms. How-
ever, the sensitive fluid showed a good stability, as it was stored at room
temperature during several months without noticing any loss of sensitiv-
ity. In addition, piezoelectric diaphragms are generally used at higher fre-
quencies, and thus the number of measuring cycles should not be an issue.
Therefore, we hypothesize that the loss of sensitivity was mostly due to
progressive ConA leakage through the nanoporous membrane. The ConA
hydrodynamic radius (respectively 3.3 and 4.4 nm in dimer and tetramer
configuration) is in fact close to the pores size distribution of the 2–4 nm
nanoporous membrane.
5.3.2 Glucose diffusion in the nanoporous membrane
The glucose diffusion properties of the 2–4 nm nanoporous alumina mem-
brane were characterized by measuring the glucose diffusion in 5 differ-
ent membranes (Fig. 5.5). As expected from the diffusion cells model (see
section 3.5.4), the dynamics of glucose diffusion is pretty well fitted by an
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Figure 5.5: Dynamics of glucose diffusion through 5 different 2–4 nm
nanoporous alumina membranes fitted by an exponential law.
exponential law. The relaxation time determined by best fitting gives a
mean relaxation time of 15.3±3.5 min. The effective diffusion coefficient
was calculated from the relaxation time following Eq. (3.27), which gives
(1.35± 0.31)× 10−4 mm2/s. From these results, it comes out that the glu-
cose diffusion coefficient in this membrane is only ∼5 times smaller than
in water (D = 6.73× 10−4 mm2/s [16]). Considering the relative standard
deviation of 23%, this value is of the same order of magnitude that the dif-
fusion coefficient in a 20 nm asymmetric alumina membrane from What-
man (1.39× 10−4 mm2/s) and much higher than its value in a nanoporous
polyethylene membrane (0.18× 10−4 mm2/s) [92]. This quite high diffu-
sivity is remarkable when considering all possible effects impeding diffu-
sion in nanoporous membranes. One important factor is the membrane
porosity, which strongly reduces the active diffusing surface in nanoporous
membranes. From SEM pictures, the porosity of the active layer with 13±2
nm alumina membranes was estimated to be 28.9%, which explains most of
the reduction in diffusion. In addition, when moving to nanofiltration ap-
plication, the free diffusion is progressively restricted when the dimensions
of the pores become comparable with those of the diffusing molecules.
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Figure 5.6: UV absorbance spectra of the retention test of the 2–4 nm alu-
mina nanoporous membrane (unstirred solutions). Each spectrum charac-
terizes the ConA permeation during 24 hours.
Factors explaining this limited diffusion may include an increased viscous
drag in the pore, particle-pore wall interactions, as well as steric effects at
the entrance of the pore [93]. With a factor of about 4 between the glucose
hydrodynamic radius (0.365 nm [94]) and the pores size, we are typically
in a situation where the high solute-to-pore ratio may restrict diffusion.
This is confirmed by previous results which reported that glucose diffu-
sion was already substantially reduced in a 7 nm nanoporous silicon ni-
tride membrane [95]. However, from the quite good diffusion properties of
the present membrane, it seems that the diffusion is only slightly affected,
which is explained by the asymmetrical structure of the membrane. In fact,
only a very thin active layer (0.5–1.5 µm) restricts diffusion whereas most
of the diffusion takes place in the support layer (50 µm), which is charac-
terized by larger pores (150–200 nm) which do not impede diffusion.
5.3.3 ConA retention by the nanoporous membrane
The ConA retention properties of 2–4 nm alumina membranes from Syn-
kera Technologies were investigated during 35 days. We recorded the UV
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Figure 5.7: Long term ConA retention of two different 2–4 nm nanoporous
alumina membranes fitted with an exponential law. ConA leakage is ex-
pressed in terms of percentage of the ConA concentration in the sensitive
fluid.
absorbance spectrum of the isotonic saline solution which was in contact
with the membrane during 24 hours (Fig. 5.6). A stronger absorbance is
observed around a wavelength of 280 nm, indicating the presence of ConA.
From these results, the ConA concentration was determined by averaging
the absorbance over a 10 nm bandwidth around the peak absorbance. The
error on the ConA concentration was estimated from the standard devi-
ation of the mean absorbance and background noise. ConA leakage was
finally expressed in terms of percentage of the ConA concentration in the
sensitive fluid (Fig. 5.7). We performed ConA retention experiments with
both well-stirred and unstirred solutions to confirm that stirring had no
deleterious effect on ConA molecules (which could have eased ConA dif-
fusion). A similar behaviour was observed for both well-stirred and un-
stirred solutions, which is explained by the constant quasi-equilibrium of
the solutions (diffusion of a very small fraction of ConA) and the long time
scale allowing diffusion in the cells. Therefore both retention experiments
can be used to estimate the retention capabilities of the membrane.
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ConA fragments leakage
Figure 5.8: Initial sensitivity reduction of the sensor which may be due to
ConA fragments leakage.
The ConA retention experiments showed a higher initial ConA leak-
age just after the beginning of the experiment. Then, after about 5–10 days
the leakage stabilized at a lower level. In particular, ConA leakage was
well described by an exponential model reaching a constant value. Initial
higher leakage could be attributed to ConA fragments which are present
in commercial ConA [96]. These fragments do not form tetramer and have
a molecular weight 2–3 times smaller than the unaltered subunit. Due to
their smaller size, ConA fragments could diffuse through the nanoporous
membrane. An initial viscosity decrease of the sensitive fluid, which may
be explained by leakage of ConA fragments, was also observed with the
sensor. In fact, when the sensor was immersed for the first time in isotonic
saline solution, the phase shift at low glucose concentration decreased dur-
ing several measurements before reaching a stable value (Fig. 5.8). How-
ever, this should not affect the accuracy of the sensor and this process may
be considered as a purification of the sensitive fluid. ConA could also be
purified prior the preparation of the sensitive fluid if a better stability is
required at the beginning of the measurement.
After that initial ConA leakage, a lower and stable value was observed
with a mean leakage per day of 0.14±0.07% of the initial concentration.
As the measured ConA concentrations were small (±0.001% [w/w]) and
close to the resolution of the UV absorbance spectrometer, the error on the
determination of ConA leakage was quite high. However, ConA leakage is
in the same range for both experiments, thus validating the experimental
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procedure despite the limited accuracy.
An almost complete retention was achieved by the membranes, which
has to be emphasized given that ConA is a small protein (3.3 nm in dimer
configuration). This also explains the good sensor stability observed for
short-term measurements, as well as the reduction in sensitivity at large
time scales. According to similar dimensions between the ConA molecules
and the membrane pores size, we could have expected a complete reten-
tion. Several hypotheses could account for this small constant ConA dif-
fusion, like a pore size distribution not as narrow as expected or some de-
fects in the membrane structure. Therefore, ConA molecules would dif-
fuse through a small fraction of pores outside the main distribution. The
small leakage rate could also suggest that most of the ConA molecules
are well confined by the nanoporous membrane. At physiological pH, the
ConA tetramer configuration is highly prevailing whereas a small fraction
of dimers remains. ConA tetramers would be confined by the membrane
whereas dimers would freely diffuse in the isotonic saline solution. With
a constant fraction of dimers and tetramers (determined by the chemical
environment), the mechanism explaining constant ConA leakage would be
a continuous dimer formation and diffusion.
Finally, the small constant diffusion also shows that the nanoporous
membranes are close to achieve a complete retention of the sensitive fluid,
which is emphasized by the much slower diffusion of ConA fragments
than glucose out of the sensor (Fig. 5.8). The ConA fragments diffusion
is slowed down by a reduced apparent porosity (small fraction of larger
pores) and/or by interactions with the pores wall of the membrane (mean-
ing that the pores are close to the confinement).
5.3.4 Pores size distribution
The nanoporous alumina membranes structure was investigated by scan-
ning electron microscopy (SEM) (Fig. 5.9). These pictures confirm the highly
ordered structure and well defined pores size that is expected for nano-
porous alumina membranes. The 2–4 nm pores were close to the resolu-
tion of the microscope and thus we were not able to get well focused pic-
tures. We therefore investigated the pores size distribution on a similar
alumina membrane with larger pores (13± 2 nm from Synkera Technolo-
gies). The pores size distribution was experimentally determined using
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100 nm
100 nm
b
a
Figure 5.9: SEM pictures showing the active layer pores size of the
nanoporous alumina membranes. (a) 2–4 nm membrane. (b) 13±2 nm
membrane.
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Figure 5.10: Experimental characterization (SEM pictures) of the pores size
distribution of the 13± 2 nm membrane fitted with a Gaussian.
particles analysis. An area encompassing 2583 pores was measured on 5
SEM pictures (Fig. 5.10). The pores size distribution is well described by a
Gaussian with a mean pores diameter of 16.49 nm and a standard deviation
of 4.93 nm, confirming a regular pores size distribution. The mean poros-
ity is 28.9±0.7%, which can be compared to the 37% reported for Whatman
alumina membranes having a nominal pores size of 20 nm [23]. These mea-
surements confirm that these alumina nanoporous membranes have a dis-
tribution not as narrow as expected, and as a consequence, a small fraction
of pores is outside the main distribution with dimensions as large as 30 nm.
The pores size distribution is also probably larger than expected for the 2-4
nm alumina membrane, which may explain the small ConA diffusion at
large time scales.
5.3.5 Pores narrowing by atomic layer deposition
In numerous applications of nanofiltration in biotechnology and bioman-
ufacturing, the precision and repeatability of the pores size of nanofiltra-
tion membranes is of high importance. Membrane manufacturing com-
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Figure 5.11: Glucose diffusion properties of 2–4 nm alumina nanoporous
membranes coated with various thicknesses of Al2O3 using atomic layer
deposition.
panies are therefore actively working on achieving precise pores size con-
trol below 2 nm while retaining narrow pore size distribution. With such
membranes characteristics, we could expect a much better long term sta-
bility of the sensor in the future. For the moment, alternative solutions
could be considered, like pores size reduction by atomic layer deposition.
This is a gas-based, surface-driven deposition technique that is uniquely
suited to coating ultrahigh aspect ratio structures such as nanopores in alu-
mina membranes. Due to its characteristics, atomic layer deposition makes
atomic scale deposition control possible, obtaining a resolution as fine as
0.1 Å per cycle.
We investigated this technology by coating the 2–4 nm membrane with
Al2O3 (coating performed by Synkera Technologies). The coated mem-
branes (3 different thicknesses) were characterized by their glucose dif-
fusion properties and compared to the non-modified 2–4 nm membrane
(Fig. 5.11). The thinner coating did not change the diffusion characteristics,
the medium coating increased the diffusion time by 50%, and the thicker
coating almost blocked the glucose diffusion. Even if the coating thickness
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fine tuning was experimental, and that several iterations were required to
arrive at a moderate pores size reduction, atomic layer deposition was ef-
fective in reducing the pores size. However, the major drawback of pores
narrowing is the reduction of the porosity, which would significantly in-
crease the response time of the sensor. The medium coating, which is char-
acterized by an increase in the diffusion time of 50%, should correspond
to a pores size of ∼1.6–3.2 nm. The pores size coating could therefore ad-
vantageously be used for small pores size adjustments but is more critical
when large reductions are required.
5.4 Conclusion
The long term stability of the sensor was investigated, showing a loss of
sensitivity of 1.3% per day during 25 days. As the nanoporous alumina
membrane is a key for the sensor stability, its diffusion and retention prop-
erties were characterized in details. The very thin active layer of the mem-
branes (0.5–1.5 µm) and quite high porosity (28.9%) gives remarkable diffu-
sion properties, with only a 5-fold reduction compared to free diffusion in
water. We also report an almost complete retention of ConA and a good sta-
bility in aqueous solution up to 35 days. However, a small ConA leakage re-
mains, which could partly explain the reduction in sensitivity at large time
scales. SEM pictures also confirm the highly ordered structure and well
defined pores size that is expected for nanoporous alumina membranes.
Finally, atomic layer deposition was effective in pores size reduction, but
the porosity was strongly affected, which means that this technique can
only be used for small pores size reduction. Therefore, these results con-
firm that nanoporous alumina membranes are well suited as size-selective
interface for this sensor. However, improvements in membrane technology
would be required for achieving a better long term stability.
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Chapter 6
Determination of glucose in
biological fluids
6.1 Introduction
The sensor is intended to be used in biological fluids such as blood or
plasma, which are by far more complex than the physiological solution
in which the measurements were demonstrated. Blood plasma essentially
contains dissolved proteins, glucose, clotting factors, mineral ions, hor-
mones and carbon dioxide. The small biomolecules present in blood plasma
could diffuse into the sensor and potentially interfere with the measure-
ment. In particular, small glycosylated biomolecules like peptides or lipids
may compete with the binding of glucose to ConA. Moreover, the adhesion
of biomolecules to surfaces could lead to biofouling of the semi-permeable
membrane, which may hinder the glucose diffusion. In addition, Mn2+
which is used to activate one of the binding sites of ConA, only appears as
trace element in blood, which could affect the stability of ConA. Checking
the adequacy of our sensor for measurements in biological fluids is there-
fore not trivial.
In this chapter, the sensor performance in human blood serum and
plasma is evaluated. The determination of glucose was first evaluated in
serum, which has the advantage to contain no anticoagulant potentially
interfering with the measurement. We also assessed the sensor in blood
plasma containing two widely used anticoagulants, heparin and EDTA
(ethylenediaminetetraacetic acid). Blood plasma is in fact more complete
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than serum, still containing fibrinogens and other clotting proteins, and is
therefore closer to the blood. It was also useful to assess the potential inter-
ferences with anticoagulants as an anticoagulant is added to the blood in
hospital applications.
6.2 Experimental description
The sensor and experimental setup used for the measurements in human
blood serum and plasma were as described in section 4.3.4. The sensor was
filled with a sensitive fluid containing 2.25% [w/w] of dextran and 0.45%
[w/w] of ConA. The actuating voltage and frequency were respectively
30 V and 2.5 Hz. Prior and after the measurement in serum and plasma, the
sensor was exposed to the same glucose concentrations in isotonic saline
solution. These reference measurements were used to assess the sensitivity
and stability of the sensor in serum and plasma.
The human serum and plasma were stored frozen at −20˚C. Before use,
0.1% sodium azide (NaN3) was added as preservative, then the human
serum was filtered (Millex HV 0.45 µm syringe filter) to remove aggre-
gates which may clog the semi-permeable membrane. The blood serum
and plasma samples were not dialyzed to keep all the small biomolecules
which could potentially interfere with the measurement. The lower glu-
cose concentration was therefore defined by the intrinsic concentration of
serum and plasma, which was measured using a standard glucose meter
(Accu-Chek). The intrinsic glucose concentration was in the physiological
range (5 mM) and concentrated D-glucose (2 M) was added to increase the
concentration to a hyperglycaemic value (20 mM).
6.3 Results and discussion
6.3.1 Measurements in human serum and plasma
The sensor was tested in human serum with glucose concentrations of 5
mM and 20 mM (Fig. 6.1). Nine changes of low and high glucose concen-
trations were performed during 17 hours. A good degree of reversibility
and stability was observed, which is promising considering all possible is-
sues arising in biological fluids. Moreover, the response time did not in-
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5 mM
20 mM
Figure 6.1: In vitro determination of glucose in human blood serum. Mea-
surements carried out in original (5 mM) and glucose added (20 mM)
serum at 25˚C.
5 mM
20 mM
Figure 6.2: In vitro determination of glucose in human blood plasma con-
taining heparin as anticoagulant.
crease with time, indicating that biofouling due to protein adsorption on
the semi-permeable membrane, if any, was not an issue and that alumina
nanoporous membranes are well-suited for biosensors size-selective inter-
face in biological fluids.
In plasma containing heparin, a quite good reversibility was also ob-
served during 16 hours (Fig. 6.2). The loss of sensitivity in plasma (heparin)
is comparable to the loss of sensitivity in serum, suggesting that heparin
does not interfere with the glucose determination. Heparin is a polysac-
charide with multiple hydroxyl groups, which is characterized by a molec-
ular weight ranging from 3 to 30 kDa. Therefore, heparin could diffuse
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5 mM
20 mM
Figure 6.3: In vitro determination of glucose in human blood plasma con-
taining EDTA as anticoagulant.
through the nanoporous membrane and potentially interfere with ConA. It
was shown that heparin binds boronic acid moieties, which are also char-
acterized by a high specific affinity for glucose [97]. A loss of sensitivity of
30% was reported in plasma containing heparin with a hydrogel-based glu-
cose sensor. Fortunately, unlike boronic acid moieties, these results suggest
that heparin does not interfere with ConA.
A progressive and high loss of sensitivity was observed in plasma con-
taining EDTA (Fig. 6.3). The demonstrator did not recover its initial sensi-
tivity when subsequently immersed in isotonic saline solution, suggesting
that EDTA irreversibly altered the sensitive fluid. EDTA is known to be
a strong chelating agent, sequestering metal ions such as Ca2+ and Fe3+.
After being bound by EDTA, metal ions remain in solution but exhibit a
reduced reactivity. EDTA is therefore probably binding the two metal ions,
Mn2+ and Ca2+, which are used to activate the glucose binding sites of
ConA. As a result, the protein undergoes a conformational change which
strongly decreases its affinity for glucose. EDTA is therefore not compatible
with this ConA-based measurement. However, this does not matter much,
given that EDTA is used for blood samples but never in the human body.
However, if required, a sensitive fluid based on boronic acid moieties could
be used, as it was shown to measure glucose in plasma containing EDTA
with a good sensitivity [97].
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Table 6.1: Sensitivity in human blood serum and plasma compared to the
sensitivity in isotonic saline solution.
Sensitivity compared to: Serum Plasma (heparin)
Solution before serum 74.2% 85.4%
Solution after serum 89.2% 97.7%
6.3.2 Molecular interference with sensitivity to glucose
From these measurements, it comes out that the sensor sensitivity in serum
partly decreases compared to the sensitivity in isotonic saline solution. Af-
ter evaluation of the glucose in serum, the sensor recovers its initial sen-
sitivity for isotonic saline solution. Therefore the loss of sensitivity is re-
versible, suggesting that small biological molecules, most likely glycosy-
lated peptides or lipids, may diffuse into the sensor and compete with the
binding of glucose to ConA.
The loss of sensitivity due to molecular interferences was evaluated by
averaging the sensor sensitivity in isotonic saline solution (prior and after
the measurement in serum/plasma) and in serum/plasma (Tab. 6.1). With
a reversible sensitivity reduction estimated to 10–20%, these measurements
indicate that there is only a minimal amount of interferences with foreign
species. Therefore, these experiments confirm that despite a slight loss in
sensitivity, the sensitivity of the sensor in serum and plasma is still high
enough for glucose monitoring.
6.3.3 Sensitive fluid stability in serum and plasma
Despite the quite good stability, a slight decrease of sensitivity was ob-
served in serum, plasma and in isotonic saline solution. For determining
whether the serum and plasma affect the measurement stability, the loss
of sensitivity of the sensor was assessed in serum/plasma, and in isotonic
saline solution prior and after the measurement in serum/plasma (Fig. 6.4).
The loss of sensitivity was slightly higher in serum than in isotonic saline
solution while it was comparable in plasma and isotonic saline solution.
We can hardly conclude on the measurement stability in serum and plasma
from these results. However, other results (data not shown) tend to show
that the sensor is not as stable in serum/plasma as in isotonic saline solu-
tion.
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Figure 6.4: Loss of sensitivity of the sensor in human blood serum (a) and
plasma (b) compared to isotonic saline solution (prior and after the mea-
surement in serum/plasma).
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Given the complexity of the serum/plasma composition, the lower sta-
bility in serum/plasma may have multiple origins. A hypothesis explain-
ing this lower stability may be ConA deactivation. In isotonic saline solu-
tion, the two metal ions used to activate the glucose binding sites of ConA
(Ca2+ and Mn2+) are present, whereas in blood only Ca2+ appears in a sig-
nificant concentration. Therefore, ConA stability in serum/plasma could
be altered by the lack of Mn2+. This hypothesis could be confirmed by
testing the sensor in isotonic saline solution without Mn2+, or alternatively
by adding Mn2+ in serum/plasma. If this hypothesis proves to be correct,
Ca2+ could be used for the two binding sites of ConA, which would have
the advantage to be closer to in vivo conditions, and may therefore improve
the sensor stability. Alternative hypotheses could include a favoured ConA
leakage through the nanoporous membrane or a deleterious effect of small
diffusing biomolecules on ConA. More testing would be required to fully
characterize the stability of the sensitive fluid in biological fluids. However,
although the stability seems lower in serum and plasma, it still remains
good enough for short term monitoring.
6.4 Conclusion
The sensor was assessed in human blood serum and plasma, showing a
quite good reversibility and stability. The response time did not increase
with time, indicating that biofouling of the nanoporous membrane, if any,
was not an issue. We report a reversible sensitivity reduction of 10–20%
which is attributed to molecular interferences, most likely small glycosy-
lated biomolecules. The sensor stability is also not as good in serum and
plasma as in isotonic saline solution, which may be explained by the lack of
Mn2+ in blood which could favour ConA deactivation. However, the sen-
sitivity and stability is still high enough for short term monitoring, which
is promising given the difficulty in measuring in biological fluids. The sen-
sor is also compatible with heparin, which could be of high importance
for hospital applications. Potential improvements include using Ca2+ for
the two binding sites of ConA as Ca2+ is present in blood, and reducing
the pores size of the nanoporous membrane to prevent most of interfering
biomolecules from entering the sensor.
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Conclusion
A viscosity-dependent affinity sensor for continuous monitoring of glu-
cose in biological fluids was developed using Concanavalin A in dextran as
sensing fluid. A nanoporous alumina membrane was used as size-selective
interface and the viscosity was detected using a flow-resisting microchan-
nel. An analytical model was derived, showing that the relaxation time
of the system is directly proportional to the liquid viscosity. The sensor
was extensively tested in isotonic saline solution for physiological blood
glucose concentrations between 2 and 20 mM, demonstrating an excellent
reversibility and stability for up to 3 days. The quite low standard devia-
tion of about 0.017 mM demonstrates the ability of this sensor for accurate
glucose monitoring. Concerning its time response, we report a value of
12.8 min at 37 ˚C, which is in line with the 10 min required for medical
applications.
The long term stability of the sensor was further investigated for eval-
uating its potential as an implantable glucose sensor. Despite the excellent
short term stability, a progressive loss of sensitivity of about 1.3% per day
was observed. Concanavalin A retention by the alumina nanoporous mem-
brane was assessed by ultraviolet absorbance spectrometry. We measured
Concanavalin A leakage of about 0.2% per day, which at least partly ex-
plains the long term sensitivity reduction of the sensor.
The sensor was finally evaluated in human blood serum and plasma,
showing a good degree of reversibility and stability over 17 hours, mean-
ing that the sensitive fluid remained chemically quite stable in presence of
plasma and that biofouling of the alumina membrane, if any, was not an
issue. A reversible decrease in sensitivity of 10–20% was observed, sug-
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gesting that small biological molecules, most likely glycosylated peptides
or lipids, may diffuse into the sensor and compete with the binding of glu-
cose to ConA. However, these experiments confirm that despite a slight
loss in sensitivity, the sensitivity of the sensor in blood plasma is still high
enough for glucose monitoring.
In conclusion, these results suggest that the combination of the ConA-
based sensitive fluid and the microviscometer is a promising sensing prin-
ciple for continuous glucose monitoring in blood. The overall performance
of the sensor still need to be improved, but technological solutions exit.
Companies are actively working on nanofiltration membranes, which shou-
ld increase the long term stability of the sensor by allowing a better reten-
tion of the sensitive fluid. In addition, a higher molecular weight sensitive
fluid like a boronic acid based polymeric mixture could also be considered
for improving the sensor stability. Finally, future research should address
the sensor miniaturization using microfabrication technologies. Further
work could also include extensive testing in human whole blood.
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